INVACARE (IVCRQ) 10-Q8 May 142014 Q1 Quarterly reportFinancial data

Company Profile

DEI_Document

DEI Document	3 Months Ended
	Mar. 31, 2014	5-May-14	5-May-14
	Mar. 31, 2014	Common Class B (Authorized 12,000 shares; 1,086 and 1,086, issued and outstanding in 2014 and 2013, respectively - no par	Common Class A [Member]
Document Information [Line Items]	'	'	'
Entity Registrant Name	'INVACARE CORPORATION	'	'
Entity Central Index Key	'0000742112	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Document Type	'10-Q	'	'
Document Period End Date	31-Mar-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'Q1	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	1,084,747	31,068,802

Consolidated_Statement_Of_Comp

Consolidated Statement Of Comprehensive Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net sales	$309,069	$331,437
Cost of Goods Sold	223,821	237,853
Gross Profit	85,248	93,584
Selling, general and administrative expense	98,021	103,235
Charge related to restructuring activities	2,240	2,522
Interest expense	806	1,117
Interest income	-68	-107
Earnings before Income Taxes	-15,751	-13,183
Income Tax Expense (Benefit)	2,225	-7,475
Income (Loss) from Continuing Operations Attributable to Parent	-17,976	-5,708
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax amounts of $0, $35, respectively	0	1,567
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax amounts of $0 and $20,080	0	39,322
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	0	40,889
Net Earnings (loss)	-17,976	35,181
Common Stock, Dividends, Per Share, Declared	$0.01	$0.01
Income (Loss) from Continuing Operations, Per Basic Share	($0.56)	($0.18)
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	$0	$1.28
Net Earnings (loss) per Share - Basic	($0.56)	$1.10
Weighted Average Shares Outstanding - Basic	32,013	31,902
Income (Loss) from Continuing Operations, Per Diluted Share	($0.56)	($0.18)
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share	$0	$1.28
Net Earnings (loss) per Share - Assuming Dilution	($0.56)	$1.10
Weighted Average Shares Outstanding - Assuming Dilution	32,301	31,934
Other Comprehensive Income (Loss), Net of Tax	'	'
Foreign currency translation adjustments	6,648	-1,498
Defined Benefit Plans	'	'
Amortization of prior service costs and unrecognized gains (losses)	708	300
Amounts arising during the year, primarily due to the addition of new participants	0	-166
Deferred tax adjustment resulting from defined benefit plan activity	-180	-48
Valuation reserve (reversal) associated with defined benefit plan activity	14	50
Current period unrealized gain (loss) on cash flow hedges	-584	1,577
Deferred tax benefit (loss) related to unrealized gain (loss) on cash flow hedges	84	-81
Other Comprehensive Income (Loss), Net of Tax	6,690	134
Comprehensive Income	($11,286)	$35,315

Consolidated_Statement_Of_Comp1

Consolidated Statement Of Comprehensive Income (Parentheticals) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Discontinued Operation, Tax Effect of Discontinued Operation	$0	$35
Discontinued Operation, Tax Effect of Income (Loss) from Disposal of Discontinued Operation	$0	$20,080

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$21,260	$29,785
Trade receivables, net	186,919	188,622
Installment receivables, net	1,590	1,562
Inventories, net	165,343	155,637
Deferred income taxes	2,714	2,761
Other current assets	39,036	41,172
Total Current Assets	416,862	419,539
Other Assets	46,030	45,936
Other Intangibles	61,064	62,584
Property and Equipment, net	103,745	106,149
Goodwill	468,314	462,226
Total Assets	1,096,015	1,096,434
Current Liabilities	'	'
Accounts payable	124,442	116,704
Accrued expenses	131,345	133,100
Accrued income taxes	12,271	12,259
Short-term debt and current maturities of long-term obligations	1,763	14,102
Liabilities of Assets Held-for-sale	0	0
Total Current Liabilities	269,821	276,165
Long-Term Debt	47,194	31,184
Other Long-Term Obligations	119,089	118,276
Shareholders' Equity	'	'
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	235,367	234,620
Retained earnings	377,644	396,016
Accumulated other comprehensive earnings	131,846	125,156
Treasury shares	-93,794	-93,794
Total Shareholders' Equity	659,911	670,809
Total Liabilities and Shareholders' Equity	1,096,015	1,096,434
Common Class A [Member]	'	'
Common Stock, Shares, Issued	34,226	34,084
Common Shares (Authorized 100,000 shares; 34,226 and 34,084 issued in 2014 and 2013, respectively) - no par	'	'
Shareholders' Equity	'	'
Common Shares	8,576	8,539
Common Class B (Authorized 12,000 shares; 1,086 and 1,086, issued and outstanding in 2014 and 2013, respectively - no par	'	'
Common Stock, Shares, Issued	1,086	1,086
Shareholders' Equity	'	'
Common Shares	$272	$272

Balance_Sheet_Parentheticals

Balance Sheet Parentheticals (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	3,158	3,158
Common Class A [Member]	'	'
Common Stock, Shares Authorized	100,000	100,000
Common Stock, Shares, Issued	34,226	34,084
Common Stock, Par or Stated Value Per Share	0	0
Common Class B [Member]	'	'
Common Stock, Shares Authorized	12,000	12,000
Common Stock, Shares, Issued	1,086	1,086
Common Stock, Par or Stated Value Per Share	0	0

Consolidated_Statement_Of_Cash

Consolidated Statement Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating Activities	'	'
Net Earnings (loss)	($17,976)	$35,181
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	0	-59,402
Depreciation and amortization	9,507	8,848
Provision for losses on trade and installment receivables	663	768
(Benefit) provision for deferred income taxes	286	-134
Provision for other deferred liabilities	141	87
Allocated Share-based Compensation Expense	699	1,160
Loss on disposals of property and equipment	83	86
Asset write-downs related to restructuring activities	638	0
Amortization of convertible debt discount	170	152
Changes in operating assets and liabilities:	'	'
Trade receivables	2,811	-20
Installment sales contracts, net	-652	-422
Inventories	-8,493	-7,661
Other current assets	2,251	2,373
Accounts payable	6,745	-15,697
Accrued expenses	-3,148	-339
Other long-term liabilities	-745	-283
Net Cash Provided (Used) by Operating Activities	-7,020	-35,303
Investing Activities	'	'
Purchases of property and equipment	-3,626	-3,865
Proceeds from sale of property and equipment	1	4
Proceeds from Divestiture of Business, net	0	144,681
(Increase) Decrease in other long-term assets	-197	-108
Other	-144	-19
Net Cash Used for Investing Activities	-3,966	140,693
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	62,525	115,950
Payments on revolving lines of credit and long-term borrowings	-60,195	-234,696
Proceeds from Stock Options Exercised	85	0
Payment of dividends	-396	-396
Net Cash Provided (Used) by Financing Activities	2,019	-119,142
Effect of exchange rate changes on cash	442	42
Increase (decrease) in cash and cash equivalents	-8,525	-13,710
Cash and cash equivalents at beginning of year	29,785	38,791
Cash and cash equivalents at end of year	$21,260	$25,081

Accounting_Policies

Accounting Policies	3 Months Ended
Accounting Policies	Mar. 31, 2014
Accounting Policies [Abstract]	'
Accounting Policies	'
	Accounting Policies

	Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home or institutional setting based upon the Company’s distribution channels, breadth of product line and net sales. The Company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and extended care markets.

	Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the Company as of March 31, 2014, the results of its operations for the three months ended March 31, 2014 and changes in its cash flow for the three months ended March 31, 2014 and 2013, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a February 28th quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the Company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year.

	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.

	Recent Accounting Pronouncements: In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-04, Liabilities (Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. This update requires an entity to measure obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, as the sum of a) the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and b) any additional amount the reporting entity expects to pay on behalf of its co-obligors. The update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. The Company adopted ASU No. 2013-04 in the first quarter of 2014 with no impact on the Company’s Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets or Statement of Cash Flows.

	In July 2013, the FASB issued ASU No. 2013-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists." ASU 2013-11 requires an entity to present an unrecognized tax benefit in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward, with limited exceptions. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. ASU 2013-11 was adopted by the Company on January 1, 2014 and did not have a significant impact on the Company's financial statements.

	In April 2014, the FASB issued ASU 2014-08 changing the presentation of discontinued operations on the statements of income and other requirements for reporting discontinued operations. Under the new standard, a disposal of a component or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the component meets the criteria to be classified as held for sale or is disposed. The amendments in this update also require additional disclosures about discontinued operations and disposal of an individually significant component of an entity that does not qualify for discontinued operations. This standard must be prospectively applied to all reporting periods presented in financial reports issued after the effective date. Early adoption is permitted for disposals that have not been reported in financial statements previously issued or available for issuance. The new accounting guidance is effective for interim and annual periods beginning after December 15, 2014. If applicable, this standard will change the presentation of the Company's financial statements but will not affect the calculation of net income, comprehensive income or earnings per share. The Company plans to adopt ASU 2014-08 effective January 1, 2015.

Discontinued_Operations_Notes

Discontinued Operations (Notes)	3 Months Ended
Discontinued Operations (Notes)	Mar. 31, 2014
Discontinued Operations [Abstract]	'
Discontinuted Operations	'
	Discontinued Operations

	On December 21, 2012, as part of the Company's globalization strategy, and to allow it to focus on its core equipment product lines, the Company entered into an agreement to sell Invacare Supply Group (ISG) and accordingly, the Company determined on that date that the "held for sale" criteria of ASC 360-10-45-9 were met. On January 18, 2013, the Company completed the sale of the ISG medical supplies business to AssuraMed, Inc. for a purchase price of $150,800,000 in cash. ISG had been operated on a stand-alone basis and reported as a reportable segment of the Company. The Company recorded a gain of $59,402,000 pre-tax in the first quarter of 2013 which represented the excess of the net sales price over the book value of the assets and liabilities of ISG, excluding cash. The sale of this business was dilutive to the Company's results. The Company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the first quarter of 2013. The Company recorded expenses related to the sale of $5,350,000, of which $5,002,000 were paid as of March 31, 2014. The net sales and earnings before income taxes of the ISG discontinued operation were $18,498,000 and $402,000 for the three months ended March 31, 2013, respectively.

	On August 6, 2013, the Company sold Champion Manufacturing, Inc. (Champion), its domestic medical recliner business for dialysis clinics, to Champion Equity Holdings, LLC for $45,000,000 in cash, which is subject to final post-closing adjustments. Champion had been operated on a stand-alone basis and reported as part of the IPG segment of the Company. The Company recorded a gain of $22,761,000 pre-tax in the third quarter of 2013, which represented the excess of the net sales price over the book value of the assets and liabilities of Champion. The sale of this business was dilutive to the Company's results. The Company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the third quarter of 2013. The Company recorded expenses related to the sale of $2,130,000, of which $1,519,000 were paid as of March 31, 2014. The gain recorded by the Company reflects the Company's estimated final purchase adjustments.

	The net sales and earnings before income taxes of the Champion discontinued operation were $6,179,000 and $1,200,000 for the three months ended March 31, 2013, respectively. Results for Champion include an interest expense allocation from continuing operations to discontinued operations of $186,000 for the three months ended March 31, 2013 as proceeds from the sale were required to be utilized to pay down debt. The interest allocation was based on the net proceeds assumed to pay down debt applying the Company's average interest rates for the periods presented.

	The Company recorded an incremental intra-period tax allocation expense to discontinued operations for the three months ended March 31, 2013 representing the cumulative intra-period allocation expense to discontinued operations based on the Company's March 31, 2013 estimate of the projected domestic taxable loss related to continuing operations for 2013.

	The Company has classified ISG and Champion as discontinued operations for all periods presented.

Receivables

Receivables	3 Months Ended
	Mar. 31, 2014
Receivables [Abstract]	'
Receivables	'
	Receivables

	Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the Company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts ($16,912,000 at March 31, 2014 and $17,715,000 at December 31, 2013) is based primarily on management’s evaluation of the financial condition of specific customers. In addition, as a result of the financing arrangement with De Lage Landen, Inc. ("DLL"), a third party financing company which the Company has worked with since 2000, management monitors the collection status of these contracts in accordance with the Company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed. The Company charges off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the consolidated balance sheet.

	The Company’s U.S. customers electing to finance their purchases can do so using DLL. In addition, the Company often provides financing directly for its Canadian customers for which DLL is not an option, as DLL typically provides financing to Canadian customers only on a limited basis. The installment receivables recorded on the books of the Company represent a single portfolio segment of finance receivables to the independent provider channel and long-term care customers. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables re-purchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by 3 payments. The Canadian installment receivables represent the second class of installment receivables which were originally financed by the Company because third party financing was not available to the HME providers. The Canadian installment receivables are typically financed for 12 months and historically have had a very low risk of default.

	The estimated allowance for uncollectible amounts and evaluation for impairment for both classes of installment receivables is based on the Company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed for impairment. The Company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the Company’s ability to enforce judgments, liens, etc.

	For purposes of granting or extending credit, the Company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for customers desiring credit greater than $250,000, which generally includes a detailed review of the customer’s financials as well as consideration of other factors such as exposure to changing reimbursement laws.

	Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the Company goes through a legal process of adjudication which typically approximates eighteen months. Any write-offs are made after the legal process has been completed. The Company has not made any changes to either its accounting policies or methodology to estimation allowances for doubtful accounts in the last twelve months.

	Installment receivables consist of the following (in thousands):


		March 31, 2014												December 31, 2013
		Current				Long-				Total				Current				Long-				Total
						Term												Term
	Installment receivables	$	3,217			$	6,164			$	9,381			$	3,242			$	5,677			$	8,919

	Less: Unearned interest	(60		)		—				(60		)		(61		)		—				(61		)

		3,157				6,164				9,321				3,181				5,677				8,858

	Allowance for doubtful accounts	(1,567		)		(4,654		)		(6,221		)		(1,619		)		(4,420		)		(6,039		)
		$	1,590			$	1,510			$	3,100			$	1,562			$	1,257			$	2,819


	Installment receivables purchased from DLL during the three months ended March 31, 2014 increased the gross installment receivables balance by $1,212,000. No sales of installment receivables were made by the Company during the quarter.

	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):


		Three Months Ended March 31, 2014				Year Ended December 31, 2013
	Balance as of beginning of period	$	6,039			$	3,823

	Current period provision	322				3,457

	Direct write-offs charged against the allowance	(140		)		(1,241		)
	Balance as of end of period	$	6,221			$	6,039



	Installment receivables by class as of March 31, 2014 consist of the following (in thousands):


		Total				Unpaid				Related				Interest
		Installment				Principal				Allowance				Income
		Receivables				Balance				for				Recognized
										Doubtful
										Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	8,014			$	8,014			$	6,136			$	—

	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,282				1,222				—				20

	Impaired Installment receivables with a related allowance recorded	85				85				85				—

	Total Canadian Installment Receivables	$	1,367			$	1,307			$	85			$	20

	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,282				1,222				—				20

Impaired Installment receivables with a related allowance recorded	8,099				8,099				6,221				—

Total Installment Receivables	$	9,381			$	9,321			$	6,221			$	20


Installment receivables by class as of December 31, 2013 consist of the following (in thousands):


	Total				Unpaid				Related				Interest
	Installment				Principal				Allowance				Income
	Receivables				Balance				for				Recognized
									Doubtful
									Accounts
U.S.
Impaired Installment receivables with a related allowance recorded	$	7,464			$	7,464			$	5,951			$	—

Canada
Non-Impaired Installment receivables with no related allowance recorded	1,367				1,306				—				101

Impaired Installment receivables with a related allowance recorded	88				88				88				—

Total Canadian Installment Receivables	$	1,455			$	1,394			$	88			$	101

Total
Non-Impaired Installment receivables with no related allowance recorded	1,367				1,306				—				101

Impaired Installment receivables with a related allowance recorded	7,552				7,552				6,039				—

Total Installment Receivables	$	8,919			$	8,858			$	6,039			$	101


Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis in accordance with ASU 2010-20. As of March 31, 2014, the Company had no U.S. installment receivables past due of 90 days or more for which the Company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management’s review when the Company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. However, while the full balance may be deemed to be impaired, the Company has historically collected a large percentage of the principal of its U.S. installment receivables.

In Canada, the Company had an immaterial amount of Canadian installment receivables which were past due of 90 days or more as of March 31, 2014 and December 31, 2013 for which the Company is still accruing interest.

The aging of the Company’s installment receivables was as follows (in thousands):


	March 31, 2014												31-Dec-13
	Total				U.S.				Canada				Total				U.S.				Canada
Current	$	1,242			$	—			$	1,242			$	1,338			$	—			$	1,338

0-30 Days Past Due	9				—				9				7				—				7

31-60 Days Past Due	11				—				11				—				—				—

61-90 Days Past Due	1				—				1				—				—				—

90+ Days Past Due	8,118				8,014				104				7,574				7,464				110

	$	9,381			$	8,014			$	1,367			$	8,919			$	7,464			$	1,455

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventory, Net [Abstract]	'
Inventories	'
	Inventories

	Inventories consist of the following (in thousands):


		31-Mar-14		31-Dec-13
	Finished goods	$	83,759	$	77,909

	Raw materials	68,590		63,123

	Work in process	12,994		14,605

		$	165,343	$	155,637

Other_Current_Assets_Notes

Other Current Assets (Notes)	3 Months Ended
	Mar. 31, 2014
Other Current Assets [Abstract]	'
Other Assets Disclosure [Text Block]	'
	Other Current Assets

	Other current assets consist of the following (in thousands):


		March 31, 2014		December 31, 2013
	Value added tax receivables	$	20,176	$	19,699

	Recoverable income taxes	1,644		2,465

	Derivatives (foreign currency forward contracts)	599		789

	Prepaid insurance	3,652		4,556

	Prepaids and other current assets	12,965		13,663

		$	39,036	$	41,172

Other_LongTerm_Assets_Notes

Other Long-Term Assets (Notes)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Investments and Other Noncurrent Assets [Text Block]	'
	Other Long-Term Assets

	Other long-term assets consist of the following (in thousands):


		March 31, 2014		December 31, 2013
	Cash surrender value of life insurance policies	$	36,887	$	36,522

	Deferred Financing Fees	597		1,096

	Investments	990		998

	Long-term installment receivables	1,510		1,257

	Long-term deferred taxes	4,741		4,741

	Other	1,305		1,322

		$	46,030	$	45,936

Property_And_Equipment

Property And Equipment	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property And Equipment	'
	Property and Equipment

	Property and equipment consist of the following (in thousands):


		March 31, 2014			December 31, 2013
	Machinery and equipment	$	363,045		$	358,061

	Land, buildings and improvements	92,169			91,389

	Furniture and fixtures	13,183			12,774

	Leasehold improvements	15,302			14,931

		483,699			477,155

	Less allowance for depreciation	(379,954		)	(371,006		)
		$	103,745		$	106,149

Goodwill_Notes

Goodwill (Notes)	3 Months Ended
Goodwill (Notes)	Mar. 31, 2014
Goodwill Disclosure [Abstract]	'
Goodwill Disclosure [Text Block]	'
	Goodwill
	The goodwill change reflected on the balance sheet from December 31, 2013 to March 31, 2014 was due to foreign currency translation.

Other_Intangibles

Other Intangibles	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Other Intangibles

	All of the Company’s other intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for $32,178,000 related to trademarks, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2013 to March 31, 2014 were the result of foreign currency translation and amortization. The Company's intangibles consist of the following (in thousands):



		March 31, 2014				December 31, 2013
		Historical		Accumulated		Historical		Accumulated
		Cost		Amortization		Cost		Amortization
	Customer Lists	$	92,408	$	66,592	$	92,637	$	65,158

	Trademarks	32,178		—		31,944		—

	License Agreements	1,382		1,382		1,393		1,393

	Developed Technology	10,028		6,621		9,916		6,390

	Patents	6,261		5,657		6,107		5,568

	Other	7,163		8,104		7,407		8,311

		$	149,420	$	88,356	$	149,404	$	86,820


	Amortization expense related to other intangibles was $2,162,000 in the first three months of 2014 and is estimated to be $8,436,000 in 2014, $7,260,000 in 2015, $5,787,000 in 2016, $2,281,000 in 2017, $2,272,000 in 2018 and $2,266,000 in 2019. Amortized intangibles are being amortized on a straight-line basis over remaining lives of 1 to 11 years with the majority of the intangibles being amortized over an average remaining life of approximately 6 years.

Current_Liabilities_Notes

Current Liabilities (Notes)	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Current Liabilities Disclosure [Text Block]	'
	Current Liabilities

	Accrued expenses consist of accruals for the following (in thousands):


		March 31, 2014		December 31, 2013
	Salaries and wages	$	40,019	$	40,252

	Taxes other than income taxes, primarily Value Added Taxes	21,827		24,525

	Warranty cost	27,540		27,393

	Freight	7,372		7,636

	Professional	7,393		6,516

	Product liability, current portion	3,403		3,183

	Rebates	1,957		1,681

	Insurance	2,535		2,549

	Interest	842		1,041

	Derivative liabilities	2,321		1,212

	Severance	3,755		3,986

	Other items, principally trade accruals	12,381		13,126

		$	131,345	$	133,100


	Accrued rebates relate to several volume incentive programs the Company offers its customers. The Company accounts for these rebates as a reduction of revenue when the products are sold in accordance with the guidance in ASC 605-50, Customer Payments and Incentives.

Warrany_Costs

Warrany Costs	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities, Current [Abstract]	'
Current Liabilities	'
	Generally, the Company's products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sales to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The Company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the Company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the Company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. The increase in the liability for pre-existing warranties in 2014 is primarily the result of product recalls. The warranty accrual as of March 31, 2014 includes additional warranty expense related to the power wheelchair joystick recall of $2,237,000 ($2,100,000 after-tax) provided for during the first quarter of 2014, which impacted the North America/HME segment by $1,171,000 after-tax and the Asia/Pacific segment by $929,000 after-tax. The increase in the Company's estimate of total cost related to this matter is attributable to higher than previously anticipated response rates from larger customers in United States and Canada. As previously indicated, the reserve is subject to adjustments as new developments change the Company's estimate of the total cost of this matter.
	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):



	Balance as of January 1, 2014	$	27,393

	Warranties provided during the period	3,119

	Settlements made during the period	(5,594		)
	Changes in liability for pre-existing warranties during the period, including expirations	2,622

	Balance as of March 31, 2014	$	27,540

LongTerm_Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt

	Debt consists of the following (in thousands):


		March 31, 2014				December 31, 2013
	Senior secured revolving credit facility, due in October 2015	$	31,794			$	28,109

	Convertible senior subordinated debentures at 4.125%, due in February 2027	10,811				10,641

	Other notes and lease obligations	6,352				6,536

		48,957				45,286

	Less current maturities of long-term debt	(1,763		)		(14,102		)
		$	47,194			$	31,184


	On January 31, 2014, the Company entered into an Amended and Restated Credit Agreement ("the Amended and Restated Credit Agreement") by and among the Company, the other Borrowers party thereto, the Guarantors party thereto, the Lenders party thereto and PNC Bank, National Association, as administrative agent, which amended and restated the Credit Agreement, dated as of October 28, 2010, by and among the Company and the other parties named therein, as amended (the “Prior Credit Agreement”).
	The Amended and Restated Credit Agreement, among other things, provides for the following:

	•	An increase in the maximum leverage ratio for the first three quarters of 2014, with quarterly ratios as described in the following table:


	Fiscal Quarter Ending	Maximum Leverage Ratio
	31-Mar-14	4.75		to	1

	30-Jun-14	4.5		to	1

	30-Sep-14	4		to	1

	December 31, 2014 and thereafter	3.5		to	1

	The quarterly minimum interest coverage ratio remains 3.50 to 1.00 in the Amended and Restated Credit Agreement.

	•	In calculating the Company’s EBITDA for purposes of determining the leverage and interest coverage ratios, the Amended and Restated Credit Agreement allows the Company to add back to EBITDA up to $20,000,000 for one-time cash restructuring charges incurred after May 30, 2013, which is an incremental increase of $5,000,000 from the terms of the Prior Credit Agreement.

	•	A decrease in the aggregate principal amount of the revolving credit facility to $100,000,000 from $250,000,000 through the maturity date of the facility in October 2015, as well as reductions in the facility’s swing line loan, optional currency and foreign borrower sublimits.

	•	Reductions in the allowances under the facility for capital expenditures (down to $25,000,000 annually), dividends, other indebtedness and liens.

	•	Further restrictions on acquisitions, share repurchases, certain investments and repurchases of convertible debt until after the Company confirms compliance with the Amended and Restated Credit Agreement following the quarter ending December 31, 2014.

	•	An increase of 25 basis points in the margin applicable to determining the interest rate on borrowings under the revolving credit facility.
	As a result of the amendment, the Company incurred $351,000 in fees in the first quarter of 2014 which were capitalized and are being amortized through October, 2015. In addition, as a result of reducing the capacity of the facility from $250,000,000 to $100,000,000, the Company wrote-off $1,070,000 in fees previously capitalized in the first quarter of 2014, which is reflected in the expense of the North America / HME segment.

	In 2007, the Company issued $135,000,000 principal amount of Convertible Senior Subordinated Debentures due 2027. The debentures are unsecured senior subordinated obligations of the Company guaranteed by substantially all of the Company’s domestic subsidiaries, pay interest at 4.125% per annum on each February 1 and August 1, and are convertible upon satisfaction of certain conditions into cash, common shares of the Company, or a combination of cash and common shares of the Company, subject to certain conditions. The debentures allow the Company to satisfy the conversion using any combination of cash or stock, and at the Company’s discretion. The Company intends to satisfy the accreted value of the debentures using cash. Assuming adequate cash on hand at the time of conversion, the Company also intends to satisfy the conversion spread using cash, as opposed to stock.

	The Company may from time to time seek to retire or purchase its 4.125% Convertible Senior Subordinated Debentures due 2027, in privately negotiated transactions or otherwise. Such purchases or exchanges, if any, will depend on prevailing market conditions, the Company's liquidity requirements, contractual restrictions and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material.

	The liability components of the Company’s convertible debt consist of the following (in thousands):


		March 31, 2014				December 31, 2013
	Principal amount of liability component	$	13,350			$	13,350

	Unamortized discount	(2,539		)		(2,709		)
	Net carrying amount of liability component	$	10,811			$	10,641


	The Company is a party to an interest rate swap agreement to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, an interest rate swap agreement for a notional amount of $12,000,000 through April 2014 was entered into that fixed the LIBOR component of the interest rate on that portion of the revolving credit facility debt at a rate of 0.54% for an effective aggregate rate 2.79%. As of March 31, 2014, the weighted average floating interest rate on revolving credit borrowings was 2.41% compared to 2.39% as of December 31, 2013.

Shareholders_Equity_Transactio

Shareholders' Equity Transactions	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Shareholders' Equity Transactions	'
	Shareholders’ Equity Transactions

	On May 16, 2013, the shareholders of the Company approved the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”), which was adopted on March 27, 2013 by the Company's Board of Directors (the “Board”). The Board adopted the 2013 Plan because the ten-year term of the Company's prior equity plan, the Invacare Corporation Amended and Restated 2003 Performance Plan (the “2003 Plan”), expired on May 21, 2013. No new awards will be granted under the 2003 Plan following its expiration, but awards granted prior to its expiration will remain in effect under their original terms.
	The 2013 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or stock appreciation rights (“SAR”) will count against the number of total shares available under the 2013 Plan as one share; and each common share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2013 Plan as two shares. Any common shares that are added back to the 2013 Plan as the result of the cancellation or forfeiture of an award granted under the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2013 Plan. Each common share that is added back to the 2013 Plan due to a cancellation or forfeiture of an award granted under the 2003 Plan will be added back as one common share.
	The Compensation and Management Development Committee of the Board (the “Compensation Committee”), in its discretion, may grant an award under the 2013 Plan to any director or employee of the Company or an affiliate. The 2013 Plan initially allows the Compensation Committee to grant up to 4,460,337 common shares in connection with the following types of awards with respect to shares of the Company's common shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock, and performance shares. The Compensation Committee also may grant performance units that are payable in cash. The Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards.
	As of March 31, 2014, there was $17,457,000 of total unrecognized compensation cost from stock-based compensation arrangements granted under the Company's 2013 Plan and previous plans, which is related to non-vested options and shares, and includes $7,230,000 related to restricted stock awards, $7,217,000 related to non-qualified stock options and $3,010,000 related to performance share awards. Total unrecognized compensation cost will be adjusted for future changes in actual and estimated forfeitures and for updated vesting assumptions for the performance share awards (see "Performance Shares and Performance Share Units" below). No tax benefit for share-based compensation was realized during 2014 or 2013 as a result of a valuation allowance against deferred tax assets.
	The amount of amount of stock-based compensation expense recognized under the provisions of Compensation-Stock Compensation, ASC 718 was as follows (in thousands):


		For the Three Months Ended March 31,
		2014				2013
	Stock-based compensation expense recognized as part of selling, general and administrative expense	$	699			$	1,160

	Stock Options

	During the three months ended March 31, 2014, the Compensation Committee did not grant any non-qualified stock options. Generally, non-qualified stock option awards typically have a term of ten years and are granted at the fair market value of the Company’s Common Shares on the date of grant. Compensation expense of $530,000 was recognized during the three months ended March 31, 2014 related to stock options previously awarded. The Company expects the compensation expense to be recognized over a weighted-average period of approximately 2 years.

	The following table summarizes information about stock option activity for the three months ended March 31, 2014:


		March 31, 2014				Weighted
						Average
						Exercise
						Price
	Options outstanding at January 1, 2014	4,533,782				$	23.86

	Granted	—				—

	Exercised	(5,411		)		15.75

	Canceled	(109,302		)		28.13

	Options outstanding at March 31, 2014	4,419,069				$	23.97

	Options exercise price range at March 31, 2014	$ 12.42 to

		$	47.8

	Options exercisable at March 31, 2014	2,967,156

	Shares available for grant at March 31, 2014*	3,625,869

	________________________

	*	Shares available for grant as of March 31, 2014 reduced by net restricted stock and restricted stock unit award and performance share and performance share unit award activity of 376,068 shares and 458,400 shares, respectively during the quarter.

	The following table summarizes information about stock options outstanding at March 31, 2014:


		Options Outstanding							Options Exercisable
	Exercise Prices	Number			Weighted Average		Weighted Average		Number	Weighted Average
		Outstanding			Remaining		Exercise Price		Exercisable	Exercise Price
		At 3/31/14			Contractual Life (Years)				At 3/31/14
	$ 12.42 – $15.00	1,256,124			7.9		$	13.95	461,239	$	13.78

	$ 15.01 – $25.00	1,563,747			4.4		22.52		1,419,474	22.38

	$ 25.01 – $35.00	912,383			4.5		25.73		893,223	25.71

	$ 35.01 – $47.80	686,815			0.3		43.23		667,740	43.22

	Total	4,419,069			4.8		$	23.97	3,441,676	$	26.13


When stock options have been awarded, they generally become exercisable over a four-year vesting period whereby options vest in equal installments each year. Options granted with graded vesting are accounted for as single options. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected dividend yield, expected stock price volatility, risk-free interest rate and expected life. The assumed expected life is based on the Company's historical analysis of option history. The expected stock price volatility is also based on actual historical volatility, and expected dividend yield is based on historical dividends as the Company has no current intention of changing its dividend policy.

The 2013 Plan provides that shares granted come from the Company's authorized but unissued common shares or treasury shares. In addition, the Company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the Company acquiring treasury shares.

Restricted Stock and Restricted Stock Units

During the three months ended March 31, 2014, in aggregate of 188,034 restricted shares and restricted share units (for non-U.S. recipients) were granted without cost to the recipients, 7,575 restricted shares were forfeited, and no awards vested. The awards granted during the first quarter are subject to cliff vesting and thus vest in their entirety on May 15, 2017. The awards of restricted shares/units are classified as equity awards as they are issued as common shares, or will be settled in common shares upon vesting. The fair value of the awards is based on the stock price on the date of grant discounted for the estimated value of dividends foregone as the awards are not eligible for dividends except to the extent vested. The fair value of the awards granted during the three months ended March 31, 2014 was $20.05 per share. Compensation expense is recognized ratably over the service period and $115,000 was recognized during the three months ended March 31, 2014 related to restricted shares/units and there were shares/units outstanding totaling 598,137 shares that were not vested. The Company expects the compensation expense to be recognized over a weighted-average period of approximately 1.5 years.

Performance Shares and Performance Share Units

During the three months ended March 31, 2014, an aggregate of 152,800 performance shares and performance share units (for non-U.S. recipients) were granted as performance awards with a 3 year performance period with payouts based on achievement of certain performance goals. There were no forfeitures, cancellations or vesting of performance awards during the period. The awards are classified as equity awards as they will be settled in common shares upon vesting. The number of shares earned will be determined at the end of the performance period based on achievement of performance criteria for January 1, 2016 through December 31, 2016 established by the Compensation Committee at the time of grant. Recipients will be entitled to receive a number of common shares equal to the number of performance shares that vest based upon the levels of achievement which may range between 0% and 150% of the target number of shares with the target being 100% of the initial grant.

The fair value of the performance awards is based on the stock price on the date of grant discounted for the estimated value of dividends foregone as the awards are not eligible for dividends except to the extent vested. The fair value of the awards granted during the three months ended March 31, 2014 was $20.05 per share. The Company assesses the probability that the performance targets will be met with expense recognized whenever it is probable that at least the minimum performance criteria will be achieved. Depending upon the Company's assessment of the probability of achievement of the goals, the Company may not recognize any expense associated with performance awards in a given period, may reverse prior expense recorded or record additional expense to make up for expense not recorded in a prior period. Compensation expense of $54,000 was recognized during the three months ended March 31, 2014 related to performance awards. The Company expects the compensation expense to be recognized over a weighted-average period of approximately 1.5 years.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	Accumulated Other Comprehensive Income (Loss) by Component

	Changes in accumulated other comprehensive income (Loss) ("OCI") during the quarter ended March 31, 2014 were as follows (in thousands):


		Foreign Currency			Long-Term Notes			Defined Benefit Plans			Derivatives			Total
	31-Dec-13	$	143,845		$	(12,566	)	$	(5,414	)	$	(709	)	$	125,156

	OCI before reclassifications	6,103			545			484			(626		)	6,506

	Amount reclassified from accumulated OCI	—			—			58			126			184

	Net current-period OCI	6,103			545			542			(500		)	6,690

	31-Mar-14	$	149,948		$	(12,021	)	$	(4,872	)	$	(1,209	)	$	131,846


	Changes in OCI during the three months ended March 31, 2013 were as follows (in thousands):


		Foreign Currency			Long-Term Notes			Defined Benefit Plans			Derivatives			Total
	December 31, 2012	$	117,465		$	2,845		$	(6,785	)	$	(782	)	$	112,743

	OCI before reclassifications	194			(1,692		)	123			1,243			(132		)

	Amount reclassified from accumulated OCI	—			—			13			253			266

	Net current-period OCI	194			(1,692		)	136			1,496			134

	March 31, 2013	$	117,659		$	1,153		$	(6,649	)	$	714		$	112,877


	Reclassifications out of accumulated OCI for the three months ended March 31, 2014 and March 31, 2013 were as follows (in thousands):


		Amount reclassified from OCI						Affected line item in the Statement of Comprehensive Income (Loss)
		Three Months Ended
		31-Mar-14			31-Mar-13
	Defined Benefit Plans

	Service and interest costs	$	58		$	15		Selling, General and Administrative

	Tax	—			(2		)	Income Taxes

	Total after tax	$	58		$	13


	Derivatives
	Foreign currency forward contracts hedging sales	$	10		$	(136	)	Net Sales

	Foreign currency forward contracts hedging purchases	133			356			Cost of Products Sold

	Interest rate swaps	—			67			Interest Expense

	Total before tax	143			287

	Tax	(17		)	(34		)	Income Taxes
	Total after tax	$	126		$	253

Charges_Related_To_Restructuri

Charges Related To Restructuring Activities	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Charges Related To Restructuring Activities	'
	Charges Related to Restructuring Activities

	The Company's restructuring charges recorded since 2011 were necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affect the Company's customers (e.g. home health care providers) and continued pricing pressures faced by the Company as a result of outsourcing by competitors to lower cost locations. In addition, restructuring decisions were also the result of reduced profitability in the North America/HME segment impacted by the FDA consent decree. While the Company's restructuring efforts have been executed on a timely basis resulting in operating cost savings, the savings have been more than offset by continued margin decline, principally as a result of product mix, reduced volumes and regulatory and compliance costs related to quality system improvements which are unrelated to the restructuring actions. The Company expects any near-term cost savings from restructuring will be offset by the continued investment in regulatory and compliance costs related to quality system improvements at least until the Company has completed its quality systems remediation efforts, and reduced net sales in the North America/HME segment at least until the Company has successfully completed the previously described third-party expert certification audit and FDA inspection and has received written notification from the FDA that the Company may resume full operations.

	The Company's restructuring commenced in the second quarter of 2011 with the Company's decision to close the Hong, Denmark assembly facility as part of the Company's ongoing globalization initiative to reduce complexity in the Company's supply chain, which is intended to reduce expenses to help offset pricing pressures. In the third quarter of 2011, the Company continued to execute on the closure of the Hong, Denmark assembly facility and initiated the closure of a smaller facility in the U.S. Charges for the quarter ended December 31, 2011 were primarily incurred at the Company's corporate headquarters for severance, with additional costs incurred as a result of the closure of the Hong, Denmark facility. The facility closures were completed in 2012 in addition to the elimination of various positions principally in the North America/Home Medical Equipment (HME) and Asia/Pacific segments.

	Charges for the year ended December 31, 2011 totaled $10,534,000 including charges for severance ($8,352,000), contract exit costs primarily related to the closure of the Hong, Denmark assembly facility ($1,788,000) and inventory write-offs ($277,000) recorded in cost of products sold and other miscellaneous costs ($117,000). The majority of the 2011 North America/HME charges were incurred for severance, primarily at the corporate headquarters as the result of the elimination of various positions principally in sales and administration in Elyria, Ohio. These eliminations were permanent reductions in workforce which primarily resulted in reduced selling, general and administrative expenses. In Europe, the charges were the result of the closure of the Company's Hong, Denmark facility. The assembly activities were transferred to other Company facilities or outsourced to third parties. This closure enabled the Company to reduce fixed operating costs related to the facility and reduce headcount with the transfer of a portion of the production to other Company facilities. The 2011 charges have now been paid out and were funded with operating cash flows.

	Charges for the year ended December 31, 2012 totaled $11,395,000 including charges for severance ($6,775,000), lease termination costs ($1,725,000), building and asset write-downs, primarily related to the closure of the Hong, Denmark assembly facility, and other miscellaneous charges in Europe and Asia/Pacific ($2,404,000) and inventory write-offs ($491,000) in Asia/Pacific recorded in cost of products sold. Severance charges were primarily incurred in the North America/HME segment ($4,242,000), Asia/Pacific segment ($1,681,000) and Europe segment ($817,000). The charges were incurred as a result of the elimination of various positions as part of the Company's globalization initiatives. In addition, a portion of the North America/HME segment severance was related to positions eliminated, principally in sales and marketing as well as manufacturing, at the Company's Taylor Street facility as a result of the FDA consent decree. The savings from these charges have been reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the Company. In Europe, positions were eliminated as a result of finalizing the exit from the manufacturing facility in Denmark and an elimination of a senior management position in Switzerland. In Asia/Pacific, at the end of October 2012, the Company's management approved a plan to restructure the Company's operations in this segment. In Australia, the Company consolidated offices / warehouses, decreased staffing and exited various activities while returning to a focus on distribution. At the Company's subsidiary, which produces microprocessor controllers, the Company decided to cease the contract manufacturing business for companies outside of the healthcare industry. Payments for the year ended December 31, 2012 were $9,381,000 and were funded with operating cash flows. The majority of the 2012 charges have now been paid out.

	Charges for the year ended December 31, 2013 totaled $9,336,000 including charges for severance ($8,282,000), lease termination costs ($698,000) and other miscellaneous charges principally in North America/HME ($356,000). Severance charges were primarily incurred in the North America/HME segment ($5,405,000), Europe segment ($1,640,000) and Asia/Pacific segment ($970,000). The charges were incurred as a result of the elimination of various positions as part of the Company's globalization initiatives. North America/HME segment severance was principally related to positions eliminated due to lost sales volumes resulting from the impact of the FDA consent decree. The savings from these charges have been reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the Company. In Europe, severance was incurred for the elimination of certain sales and supply chain positions. In Asia/Pacific, severance was principally incurred at the Company's microprocessor controller production subsidiary as a result of the Company's decision in 2012 to cease the contract manufacturing business for companies outside of the healthcare industry. The lease termination costs were principally related to Australia as a result of the restructuring announced in 2012. Payments for the year ended December 31, 2013 were $11,844,000 and were funded with operating cash flows and cash on hand. The majority of the 2013 charges are expected to be paid out in 2014.

	Restructuring continued during 2014 resulting in restructuring charges of $2,240,000 in the first three months of 2014 related to severance costs ($1,521,000) and other costs ($719,000), which principally include a building write-down in the IPG segment. The severance costs were incurred principally in the NA/HME segment, and to a lesser extent the Europe and IPG segments. The building write-down in the IPG segment was associated with the previously announced closure of the London, Canada facility. Payments for the three months ended March 31, 2014 were $2,625,000 and were funded with the Company's credit facility. The majority of the outstanding charge accruals at March 31, 2014 are expected to be paid out within the next twelve months.

	There have been no material changes in accrued balances related to the charges, either as a result of revisions in the plan or changes in estimates. In addition, the savings anticipated as a result of the Company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting Selling, General and Administrative expenses, and to a lesser extent, Costs of Products Sold. However, to date, these savings have been more than offset by continued margin decline, principally as a result of product mix, and higher regulatory and compliance costs related to quality system improvements and reduced net sales volumes primarily related to mobility and seating products impacted by the consent decree, which are unrelated to the restructuring actions.

	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands):


		Severance				Product Line				Contract				Other				Total
						Discontinuance				Terminations
	December 31, 2010 Balance
	Total	$	—			$	—			$	—			$	—			$	—

	Charges
	NA/HME	4,755				—				—				4				4,759

	IPG	123				—				—				—				123

	Europe	3,288				277				1,788				113				5,466

	Asia/Pacific	186				—				—				—				186

	Total	8,352				277				1,788				117				10,534

	Payments
	NA/HME	(1,663		)		—				—				(4		)		(1,667		)

	IPG	(52		)		—				—				—				(52		)

	Europe	(1,546		)		(277		)		(1,714		)		(113		)		(3,650		)
	Asia/Pacific	(186		)		—				—				—				(186		)

	Total	(3,447		)		(277		)		(1,714		)		(117		)		(5,555		)
	December 31, 2011 Balance
	NA/HME	3,092				—				—				—				3,092

	IPG	71				—				—				—				71

	Europe	1,742				—				74				—				1,816

	Asia/Pacific	—				—				—				—				—

	Total	4,905				—				74				—				4,979

	Charges
	NA/HME	4,242				—				5				—				4,247

	IPG	35				—				—				—				35

	Europe	817				—				53				1,223				2,093

	Asia/Pacific	1,681				491				1,667				1,181				5,020

Total	6,775				491				1,725				2,404				11,395

Payments
NA/HME	(3,587		)		—				(5		)		—				(3,592		)

IPG	(106		)		—				—				—				(106		)

Europe	(1,964		)		—				(127		)		(1,223		)		(3,314		)

Asia/Pacific	(812		)		(340		)		(42		)		(1,175		)		(2,369		)
Total	(6,469		)		(340		)		(174		)		(2,398		)		(9,381		)
December 31, 2012 Balance
NA/HME	3,747				—				—				—				3,747

IPG	—				—				—				—				—

Europe	595				—				—				—				595

Asia/Pacific	869				151				1,625				6				2,651

Total	5,211				151				1,625				6				6,993





	Severance				Product Line				Contract				Other				Total
					Discontinuance				Terminations
Charges
NA/HME	5,405				—				164				353				5,922

IPG	267				—				—				—				267

Europe	1,640				—				—				—				1,640

Asia/Pacific	970				—				534				3				1,507

Total	8,282				—				698				356				9,336

Payments
NA/HME	(6,347		)		—				(164		)		(353		)		(6,864		)

IPG	(175		)		—				—				—				(175		)

Europe	(1,146		)		—				—				—				(1,146		)

Asia/Pacific	(1,839		)		(151		)		(1,660		)		(9		)		(3,659		)
Total	(9,507		)		(151		)		(1,824		)		(362		)		(11,844		)
December 31, 2013 Balance
NA/HME	2,805				—				—				—				2,805

IPG	92				—				—				—				92

Europe	1,089				—				—				—				1,089

Asia/Pacific	—				—				499				—				499

	3,986				—				499				—				4,485

Charges
NA/HME	803				—				—				—				803

IPG	340				—				—				719				1,059

Europe	378				—				—				—				378

Asia/Pacific	—				—				—				—				—

Total	1,521				—				—				719				2,240

Payments
NA/HME	(1,120		)		—				—				—				(1,120		)

IPG	(35		)		—				—				(719		)		(754		)

Europe	(597		)		—				—				—				(597		)

Asia/Pacific	—				—				(154		)		—				(154		)

Total	(1,752		)		—				(154		)		(719		)		(2,625		)

March 31, 2014 Balance
NA/HME	2,488				—				—				—				2,488

IPG	397				—				—				—				397

Europe	870				—				—				—				870

Asia/Pacific	—				—				345				—				345

	$	3,755			$	—			$	345			$	—			$	4,100

Income_Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes

	The Company had an effective tax rate provision of 14.1% on losses before tax from continuing operations for the three months ended March 31, 2014 compared to an expected benefit at the U.S. statutory rate of 35%. The Company's effective tax rate for the three months ended March 31, 2014 was greater than the U.S. federal statutory rate, principally due to the negative impact of the Company not being able to record tax benefits related to the significant losses in countries which had tax valuation allowances. The rate was benefitted by taxes outside the United States, excluding countries with tax valuation allowance, at an effective rate lower than the U.S. statutory rate.

	The Company had an effective tax rate benefit of 56.7% on losses before tax from continuing operations for the three months ended March 31, 2013 compared to the expected U.S. statutory rate of 35%. The Company's effective tax rate for the three months ended March 31, 2013 was a greater benefit than the U.S. federal statutory rate, principally due to an intraperiod tax allocation resulting in recognizing a tax benefit for the continuing loss in the United States as part of the annual effective rate. The rate was also benefitted by taxes outside the United States, excluding countries with tax valuation allowances that were in losses in 2013, at an effective rate lower than the U.S. statutory rate.

Net_Earnings_Loss_Per_Common_S

Net Earnings (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Earnings (Loss) Per Common Share	'
	Net Earnings (Loss) Per Common Share

	The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated.


	(In thousands except per share data)	For the Three Months Ended March 31,
		2014			2013
	Basic
	Average common shares outstanding	32,013			31,902


	Net loss from continuing operations	$	(17,976	)	$	(5,708	)
	Net earnings from discontinued operations	$	—		$	40,889

	Net earnings (loss)	$	(17,976	)	$	35,181


	Net loss per common share from continuing operations	$	(0.56	)	$	(0.18	)
	Net earnings per common share from discontinued operations	$	—		$	1.28

	Net earnings (loss) per common share	$	(0.56	)	$	1.1


	Diluted
	Average common shares outstanding	32,013			31,902

	Shares related to convertible debt	—			—

	Stock options and awards	288			32

	Average common shares assuming dilution	32,301			31,934


	Net loss from continuing operations	$	(17,976	)	$	(5,708	)
	Net earnings from discontinued operations	$	—		$	40,889

	Net earnings (loss)	$	(17,976	)	$	35,181


	Net loss per common share from continuing operations *	$	(0.56	)	$	(0.18	)
	Net earnings per common share from discontinued operations	$	—		$	1.28

	Net earnings (loss) per common share *	$	(0.56	)	$	1.1


	* Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the period in which there was a net loss.

	At March 31, 2014, 2,525,703 shares associated with stock options were excluded from the average common shares assuming dilution for the three months ended March 31, 2014 as they were anti-dilutive. At March 31, 2014, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value price of $20.57 for the three months ended March 31, 2014. At March 31, 2013, 5,103,319 shares associated with stock options were excluded from the average common shares assuming dilution for the three months ended March 31, 2013 as they were anti-dilutive. At March 31, 2013, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value price of $15.41 for the three months ended March 31, 2013. For the three months ended March 31, 2014 and March 31, 2013, there were no shares necessary to settle a conversion spread on the convertible notes to be included in the common shares assuming dilution as the average market price of the Company stock for these periods did not exceed the conversion price.

Concentration_Of_Credit_Risk

Concentration Of Credit Risk	3 Months Ended
Concentration Of Credit Risk	Mar. 31, 2014
Risks and Uncertainties [Abstract]	'
Concentration Of Credit Risk	'
	Concentration of Credit Risk

	The Company manufactures and distributes durable medical equipment to the home health care, retail and extended care markets. The Company performs credit evaluations of its customers’ financial condition. The Company utilizes De Lage Landen, Inc. (“DLL”), a third party financing company, to provide the majority of future lease financing to the Company’s North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The Company retains a recourse obligation of $4,493,000 at March 31, 2014 to DLL for events of default under the contracts, which total $40,528,000 at March 31, 2014. The Company's recourse is re-evaluated by DLL biannually, considers activity between the biannual dates and excludes any receivables repurchased by the Company from DLL. The Company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4. Credit losses are provided for in the financial statements.

	Substantially all of the Company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. The Company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the Company’s customers.

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives	'
	Derivatives

	ASC 815 requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.

	Cash Flow Hedging Strategy

	The Company uses derivative instruments in an attempt to manage its exposure to foreign currency exchange risk and interest rate risk. Foreign forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. Interest rate swaps are, at times, utilized to manage interest rate risk associated with the Company’s fixed and floating-rate borrowings.

	The Company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the Company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change.

	During the first three months of 2014 and 2013, the Company was a party to interest rate swap agreements that qualified as cash flow hedges and effectively converted floating-rate debt to fixed-rate debt, so the Company could avoid the risk of changes in market interest rates. The gains or losses on interest rate swaps are reflected in interest expense on the consolidated statement of comprehensive income (loss).

	To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the Company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The Company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months.

	The Company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the Company generally limits its hedges to between 60% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, the majority of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $33,623,000 matured during the three months ended March 31, 2014 compared to forward contracts with a total notional amount in USD of $33,494,000 that matured during the three months ended March 31, 2013.

	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):


		March 31, 2014							December 31, 2013
		Notional			Unrealized				Notional			Unrealized
		Amount			Net Gain				Amount			Net Gain
					(Loss)							(Loss)
	USD / AUD	$	1,650		$	(54	)		$	—		$	—

	USD / CNY	10,600			(207		)		11,730			(66		)

	USD / CHF	339			(8		)		486			4

	USD / EUR	39,317			(767		)		51,106			(168		)

	USD / GBP	2,132			(85		)		2,686			(45		)

	USD / NZD	1,204			(47		)		—			—

	USD / SEK	1,734			(5		)		2,485			58

	USD / MXP	8,683			174				5,960			102

	EUR / AUD	500			(16		)		—			—

	EUR / CAD	1,326			71				1,710			(1		)

	EUR / CHF	2,322			32				2,654			1

	EUR / DKK	1,096			(3		)		1,382			(5		)

	EUR / GBP	23,440			(601		)		29,614			(501		)

	EUR / SEK	2,790			11				3,432			75

	EUR / NOK	2,480			31				3,135			66

	EUR / NZD	5,679			224				6,959			(111		)

	AUD / CAD	1,323			(18		)		—			—

	AUD / NZD	883			(6		)		—			—

	GBP / CHF	661			(16		)		837			(26		)

	GBP / SEK	1,644			(78		)		2,078			(101		)

DKK / SEK	3,981			(29		)		5,337			(94		)

NOK / SEK	2,575			24				3,418			31

	$	116,359		$	(1,373	)		$	135,009		$	(781	)


Derivatives Not Qualifying or Designated for Hedge Accounting Treatment

The Company also utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the Company in 2014 or 2013 related to these contracts and the associated short-term intercompany trading receivables and payables.

Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2014 and 2013, respectively, and outstanding were as follows (in thousands USD):


	March 31, 2014							March 31, 2013
	Notional			Gain				Notional			Gain
	Amount			(Loss)				Amount			(Loss)
AUD / USD	$	2,100		$	(52	)		$	—		$	—

CAD / USD	5,612			(184		)		24,120			$	(544	)

CNY / USD	1,482			(40		)		—			—

EUR / USD	15,138			18				—			—

CHF / USD	678			1				—			—

DKK / USD	6,636			13				22,970			(598		)

NZD / USD	5,000			(86		)		—			—

EUR / AUD	—			—				1,500			(35		)

EUR / DKK	5,548			(9		)		—			—

AUD / EUR	2,106			(6		)		—			—

AUD / GBP	—			—				2,966			6

	$	44,300		$	(345	)		$	51,556		$	(1,171	)


The fair values of the Company’s derivative instruments were as follows (in thousands):


	March 31, 2014							December 31, 2013
	Assets			Liabilities				Assets			Liabilities
Derivatives designated as hedging instruments under ASC 815
Foreign currency forward exchange contracts	$	568		$	1,941			$	414		$	1,195

Interest rate swap contracts	—			4				—			12

Derivatives not designated as hedging instruments under ASC 815
Foreign currency forward exchange contracts	31			376				375			5

Total derivatives	$	599		$	2,321			$	789		$	1,212


The fair values of the Company’s foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets.

The effect of derivative instruments on the Statement of Comprehensive Income (Loss) and Other Comprehensive Income (OCI) was as follows (in thousands):


Derivatives in ASC 815 cash flow hedge	Amount of Gain			Amount of Gain (Loss)				Amount of Gain (Loss)
relationships	(Loss) Recognized in OCI on Derivatives			Reclassified from				Recognized in Income on
	(Effective Portion)			Accumulated OCI into				Derivatives (Ineffective Portion
				Income (Effective				and Amount Excluded from
				Portion)				Effectiveness Testing)
Three months ended March 31, 2014
Foreign currency forward exchange contracts	$	(382	)	$	(126	)		$	—

Interest rate swap contracts	8			—				—

	$	(374	)	$	(126	)		$	—

Three months ended March 31, 2013
Foreign currency forward exchange contracts	$	1,601		$	(220	)		$	57

Interest rate swap contracts	263			(67		)		—

	$	1,864		$	(287	)		$	57


Derivatives not designated as hedging								Amount of Gain (Loss)
instruments under ASC 815								Recognized in Income on Derivatives
Three months ended March 31, 2014
Foreign currency forward exchange contracts								$	(345	)
Three months ended March 31, 2013
Foreign currency forward exchange contracts								$	(1,171	)

The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales or cost of product sold for hedges of inventory purchases. For the three months ended March 31, 2014, net sales were decreased by $10,000 and cost of product sold was increased by $133,000 for a net realized loss of $143,000. For the three months ended March 31, 2013, net sales were increased by $136,000 and cost of product sold was increased by $356,000 for a net realized loss of $220,000.

The Company recognized expense of $11,000 for the three and three months ended March 31, 2014 compared to expense of $226,000 for three months ended March 31, 2013 related to interest rate swap agreements, which is reflected in interest expense on the consolidated statement of comprehensive income (loss).

A loss of $345,000 versus a loss of $1,171,000 was recognized in selling, general and administrative (SG&A) expenses for the three months ended March 31, 2014 and March 31, 2013, respectively, on ineffective forward contracts and forward contracts not designated as hedging instruments that are entered into to offset gains/losses also recorded in SG&A expenses on intercompany trade receivables or payables. Any gains/losses on the non-designated hedging instruments were substantially offset by gains/losses also recorded in SG&A expenses on intercompany trade payables.

The Company has entered into foreign currency forward exchange contracts and interest rate swap contracts (the “agreements”) with various bank counterparties, each of which are subject to provisions which are similar to a master netting agreement. The agreements provide for a net settlement payment in a single currency upon a default by the Company. Furthermore, the agreements provide the counterparty with a right of set off in the event of a default that would enable the counterparty to offset any net payment due by the counterparty to the Company under the applicable agreement by any amount due by the Company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the Company's Credit Agreement to reduce any derivative settlement amounts owed to the Company under the derivative contract by any amounts owed to the counterparty by the Company under the Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the Company under the agreement in the event of a default by the Company under another agreement with the same counterparty. The Company does not present any derivatives on a net basis in its financial statements and all derivative balances presented are subject to provisions that are similar to master netting agreements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Values

	Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable.

	The following table provides a summary of the Company’s assets and liabilities that are measured on a recurring basis (in thousands).


					Basis for Fair Value Measurements at Reporting Date
					Quoted Prices in Active			Significant				Significant
					Markets for Identical			Other				Other
					Assets / (Liabilities)			Observable				Unobservable
								Inputs				Inputs
		Total			Level I			Level II				Level III
	31-Mar-14
	Forward Exchange Contracts—net	$	(1,718	)	—			$	(1,718	)		—

	Interest Rate Swap Agreements—net	(4		)	—			(4		)		—

	31-Dec-13
	Forward Exchange Contracts—net	$	(411	)	—			$	(411	)		—

	Interest Rate Swap Agreements—net	(12		)	—			(12		)		—


	Forward Contracts: The Company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans and third party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge the following currencies: AUD, CAD, CHF, CNY, DKK, EUR, GBP, MXP, NOK, NZD, SEK and USD. The Company does not use derivative financial instruments for speculative purposes. Fair values for the Company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities.

	The carrying values and fair values of the Company’s financial instruments are as follows (in thousands):


		March 31, 2014							December 31, 2013
		Carrying			Fair Value				Carrying				Fair Value
		Value							Value
	Cash and cash equivalents	$	21,260		$	21,260			$	29,785			$	29,785

	Other investments	990			990				998				998

	Installment receivables, net of reserves	3,100			3,100				2,819				2,819

	Long-term debt (including current maturities of long-term debt)	(48,957		)	(48,471		)		(45,286		)		(46,124		)
	Forward contracts in Other Current Assets	599			599				789				789

	Forward contracts in Accrued Expenses	(2,317		)	(2,317		)		(1,200		)		(1,200		)
	Interest rate swap agreements in Accrued Expenses	(4		)	(4		)		(12		)		(12		)

	The Company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions:

	Cash, cash equivalents: The carrying value reported in the balance sheet for cash, cash equivalents equals its fair value.
	Other investments: The Company has made other investments in limited partnerships and non-marketable equity securities, which are accounted for using the cost method, adjusted for any estimated declines in value. These investments were acquired in private placements and there are no quoted market prices or stated rates of return. The Company does not have the ability to easily sell these investments.
	Installment receivables: The carrying value reported in the balance sheet for installment receivables approximates its fair value. The interest rates associated with these receivables have not varied significantly since inception. Management believes that after consideration of the credit risk, the net book value of the installment receivables approximates market value.
	Long-term debt: Fair values for the Company’s convertible debt is based on quoted market-based estimates as of the end of the period, while the revolving credit facility fair values are based upon the Company’s estimate of the market for similar borrowing arrangements. The fair values are deemed to be categorized as Level 2 in the fair value hierarchy.
	Forward contracts and interest rate swaps: Fair values for the Company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities, while the fair values of the interest rate swaps are based on model-derived calculations using inputs that are observable in active markets.

Business_Segments

Business Segments	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Business Segments	'
	Business Segments

	The Company operates in four primary business segments: North America/Home Medical Equipment (North America/HME), Institutional Products Group (IPG), Europe and Asia/Pacific.

	The North America/HME segment sells each of three primary product lines, which includes: lifestyle, mobility and seating and respiratory therapy products. IPG sells or rents long-term care medical equipment, health care furnishings and accessory products. Europe and Asia/Pacific sell product lines similar to North America/HME and IPG. Each business segment sells to the home health care, retail and extended care markets.

	The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the Company’s consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance except for Asia/Pacific due to its significant intercompany sales volume relative to the segment.

	The information by segment is as follows (in thousands):


		For the Three Months Ended
		March 31, 2014			March 31, 2013
	Revenues from external customers
	North America/HME	$	129,110		$	151,882

	Institutional Products Group	25,136			29,224

	Europe	142,768			137,634

	Asia/Pacific	12,055			12,697

	Consolidated	$	309,069		$	331,437

	Intersegment revenues
	North America/HME	$	18,673		$	18,836

	Institutional Products Group	1,573			1,107

	Europe	1,682			1,953

	Asia/Pacific	6,192			6,882

	Consolidated	$	28,120		$	28,778

	Restructuring charges before income taxes
	North America/HME	$	803		$	1,679

	Institutional Products Group	1,059			188

	Europe	378			115

	Asia/Pacific	—			540

	Consolidated	$	2,240		$	2,522

	Earnings (loss) before income taxes
	North America/HME	$	(16,799	)	$	(11,179	)
	Institutional Products Group	(251		)	474

	Europe	9,246			5,843

	Asia/Pacific	(2,801		)	(2,261		)
	All Other (1)	(5,146		)	(6,060		)
	Consolidated	$	(15,751	)	$	(13,183	)
	________________________

	-1	Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments.

Contingencies

Contingencies	3 Months Ended
Contingencies	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies

	General
	In the ordinary course of its business, the Company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits that the Company faces in the United States have been referred to the Company's captive insurance company and/or excess insurance carriers while all non-U.S. lawsuits have been referred to the Company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the Company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures.
	As a medical device manufacturer, the Company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting and other practices of health care suppliers and manufacturers are all subject to government scrutiny. The Company's facilities are subject to periodic inspection by the FDA. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, including disqualification from Medicare and other reimbursement programs, which could have a material adverse effect on the Company's business.
	On February 14, 2014, an amended complaint, in a lawsuit originally instituted on August 26, 2013, was filed against Invacare Corporation, Gerald B. Blouch, A. Malachi Mixon III and Patricia Stumpp, as well as outside directors Dale C. LaPorte, Michael F. Delaney and Charles S. Robb, in the U.S. District Court for the Northern District of Ohio, alleging that the defendants breached their fiduciary duties and violated the Employment Retirement Security Act (ERISA) in the administration and maintenance of the Company stock fund in the Company’s Retirement Savings Plan (401(k) Plan). The lawsuit seeks class certification and unspecified damages and attorneys' fees for participants in the Company's stock fund of the 401(k) Plan between July 22, 2010 and the present. This lawsuit has been referred to the Company's insurance carriers. The Company intends to vigorously defend this lawsuit.

	Medical Device Regulatory Matters
	The FDA regulates virtually all aspects of the development, testing, manufacturing, labeling, promotion, distribution and marketing of a medical device. The Company and its products are subject to the laws and regulations of the FDA and other regulatory bodies in the various jurisdictions where the Company's products are manufactured or sold. The Company's failure to comply with the regulatory requirements of the FDA and other applicable medical device regulatory requirements can subject the Company to administrative or judicially imposed sanctions. These sanctions include injunctions, consent decrees, warning letters, civil penalties, criminal penalties, product seizure or detention, product recalls and total or partial suspension of production.
	In December 2012, the Company reached agreement with the FDA on the terms of the consent decree of injunction with respect to the Company's Corporate facility and its Taylor Street wheelchair manufacturing facility in Elyria, Ohio. A complaint and consent decree were filed in the U.S. District Court for the Northern District of Ohio, and on December 21, 2012. The Court approved the consent decree and it became effective. The consent decree limits the Company's manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility. The decree also temporarily limited design activities related to wheelchairs and power beds that take place at the impacted Elyria, Ohio facilities. The Company is entitled to continue to produce from the Taylor Street manufacturing facility certain medically necessary wheelchairs provided that documentation and record-keeping requirements are followed, as well as ongoing replacement, service and repair of products already in use, under terms delineated in the consent decree. Under the terms of the consent decree, in order to resume full operations at the impacted facilities, the Company must successfully complete a third-party expert certification audit at the impacted Elyria facilities, which is comprised of three distinct reports that must be submitted to, and accepted by, the FDA. After the final certification report is submitted to the FDA, as well as the Company’s own report as to its compliance status together with its responses to any observations in the certification report, the FDA is expected to inspect the Company's Corporate and Taylor Street facilities to determine whether they are in compliance with the Quality System Regulation (QSR) governing the manufacture of medical devices and the terms of the consent decree. If the FDA is satisfied with the Company's compliance, the FDA will provide written notification that the Company is permitted to resume full operations at the impacted facilities.
	During 2013, the Company completed the first two of the expert certification audits, and the FDA found the results of both to be acceptable. In these reports, the third-party expert certified that the Company's equipment and process validation procedures and its design control systems are compliant with the FDA's QSR. As a result of the FDA's acceptance of the first certification report on May 13, 2013, the Taylor Street facility was able to resume supplying parts and components for the further manufacturing of medical devices at other Company facilities. The Company's receipt of the FDA's acceptance of the second certification report on July 15, 2013, resulted in the Company being able to resume design activities at the impacted facilities related to power wheelchairs and power beds.
	The third, most comprehensive expert certification audit is a comprehensive review of the Company's compliance with the FDA's QSR at the impacted Elyria facilities. At the time of filing this Quarterly Report on Form 10-Q, the Company is continuing its work with the third-party expert auditor, as the auditor proceeds with the final certification audit process. This audit is the most comprehensive and challenging of the three expert certification audits, and it encompasses all areas of the Company's Corporate and Taylor Street quality system, including the two areas where the third-party expert had previously indicated more work was required. The Company respects the comprehensive nature of the audit process and is working diligently with the third-party expert auditor with the ultimate goal of demonstrating the Company's compliance to the FDA.
	The Company cannot predict the timing of the completion or the outcome of the third-party expert’s final certification report. However, after the expert's certification report is completed and submitted to the FDA, as well as the Company’s own report related to its compliance status together with its responses to any observations in the certification report, the FDA is expected to inspect the Company's Corporate and Taylor Street facilities to determine whether they are in compliance with the FDA's QSR and the consent decree. If the FDA is satisfied with the Company's compliance, the FDA will provide written notification that the Company is permitted to resume full operations at the impacted facilities.
	After resumption of full operations, the Company must undergo five years of audits by a third-party expert auditor to determine whether the facilities are in continuous compliance with FDA's QSR and the consent decree. The auditor will inspect the Corporate and Taylor Street facilities’ activities every six months during the first year following the resumption of full operations and then every 12 months for the next four years thereafter.
	As described above, because the limitations on production are expected to be temporary in nature, and partial production is allowed, the Company does not anticipate any major repair, replacement or scrapping of its fixed assets at the Taylor Street manufacturing facility. Based on the Company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the utilization of such raw material and with respect to expected future cash flows from production at the Taylor Street manufacturing facility, the Company concluded that there is no impairment in the value of the fixed assets related to the Taylor Street manufacturing facility at March 31, 2014.
	The majority of the production from the Taylor Street facility is "made to order" custom wheelchairs for customers and, as a result, there was not a significant amount of finished goods inventory on hand at March 31, 2014, and the inventory is expected to be fully utilized. Accordingly, the Company concluded that there was not an impairment of the work in process and finished goods at the Taylor Street facility at March 31, 2014. Further, based on its analysis of the raw material inventory at the Taylor Street facility and the Company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the time frame for completion of the third-party expert certification audits and FDA inspection, the Company concluded that the value of the inventory was not excessive or impaired at March 31, 2014. However, if the Company's expectations regarding the impacts of the limitations in the consent decree or the time frame for completion of the third-party expert certification audits and FDA inspection were to change, the Company may, in future periods, conclude that an impairment exists with respect to its fixed assets or inventory at the Taylor Street facility.
	North America/HME and Asia/Pacific segments: The North America/HME segment is the segment primarily impacted by the limitations in the FDA consent decree. However, the Asia/Pacific segment also is negatively affected as a result of the consent decree due to the lower sales volume of microprocessor controllers. During 2012, before the effective date of the consent decree, the Company started to experience decreases in net sales in the North America/HME and Asia/Pacific segments. Those decreases were primarily related to delays in new product introductions, uncertainty on the part of the Company's customers as they coped with prepayment reviews and post-payment audits by the Centers for Medicare and Medicaid Services ("CMS") and contemplated their participation in the next round of National Competitive Bidding ("NCB"), and, the Company believes, uncertainty regarding the resolution of the consent decree which limited the Company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. The negative effect of the consent decree on customer orders and net sales has been considerable, and the Company expects to experience continued low levels in net sales as a result of the limitations imposed by the consent decree. The Company expects to continue to experience lower levels of net sales in the North America/HME and Asia/Pacific segments at least until it has successfully completed the previously-described third-party expert certification audit and FDA inspection and has received written notification from the FDA that the Company may resume full operations at the Corporate and Taylor Street facilities. Even after the Company is permitted to resume full operations at the affected facilities, it is uncertain as to whether, or how quickly, the Company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, when compared to the Company's 2010 results, the limitations in the consent decree had, and likely will continue to have, a material adverse effect on the Company's business, financial condition and results of operations.
	For additional information regarding the consent decree, please see the following sections of the Company's Annual Report on Form 10-K for the year ending December 31, 2013: Item 1. Business - Government Regulation and Item 1A. Risk Factors and the following sections of this Quarterly Report on Form 10-Q: Item 1. Legal Proceedings; and Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Outlook and - Liquidity and Capital Resources.
	In the first quarter of 2014, the Company recorded additional warranty expense related to the power wheelchair joystick recall of $2,237,000 ($2,100,000 after-tax), which impacted the North America/HME segment by $1,171,000 after-tax and the Asia/Pacific segment by $929,000 after-tax. The increase in the Company's estimate of total cost related to this matter is attributable to higher than previously anticipated response rates from larger customers in United States and Canada. As previously indicated, the reserve is subject to adjustments as new developments change the Company's estimate of the total cost of this matter.
	In addition, in December 2010, the Company received a warning letter from the FDA related to quality system processes and procedures at the Company's Sanford, Florida facility. The Company has taken actions which it believes address all of the FDA's concerns in the warning letter. However, the results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA warning letter could materially and adversely affect the Company's business, financial condition, and results of operations.
	Any of the above contingencies could have an adverse impact on the Company's financial condition or results of operations.

Supplemental_Guarantor_Informa

Supplemental Guarantor Information	3 Months Ended
	Mar. 31, 2014
Supplemental Guarantor Information [Abstract]	'
Guarantees [Text Block]	'
	Supplemental Guarantor Information

	Effective February 12, 2007, substantially all of the domestic subsidiaries (the “Guarantor Subsidiaries”) of the Company became guarantors of the indebtedness of Invacare Corporation under its 4.125% Convertible Senior Subordinated Debentures due 2027 (the “Debentures”) with an original aggregate principal amount of $135,000,000. The majority of the Company’s subsidiaries are not guaranteeing the indebtedness of the Debentures (the “Non-Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries has fully and unconditionally guaranteed, on a joint and several basis, to pay principal, premium, and interest related to the Debentures and each of the Guarantor Subsidiaries are directly or indirectly 100%-owned subsidiaries of the Company. Specifically, the Debentures are guaranteed on an unsecured senior subordinated basis by all of the Company's existing domestic subsidiaries (other than the Company's captive insurance subsidiary and any receivables subsidiaries) and certain future direct and indirect 100% owned domestic subsidiaries. All of the guarantors are released and relieved of any liability under such guarantees upon the satisfaction and discharge of the indenture governing the debentures and the payment in full of the debentures. Additionally, in the event any subsidiary guarantor no longer guarantees any of the Company's existing or future senior debt incurred in a public or private U.S. capital markets transaction, such guarantor shall be released and relieved of any liability which it has under the indenture governing the debentures.

	Presented below are the consolidating condensed financial statements of Invacare Corporation (Parent), its combined Guarantor Subsidiaries and combined Non-Guarantor Subsidiaries with their investments in subsidiaries accounted for using the equity method. The Company does not believe that separate financial statements of the Guarantor Subsidiaries are material to investors and accordingly, separate financial statements and other disclosures related to the Guarantor Subsidiaries are not presented.

	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)


		The				Combined				Combined				Eliminations				Total
		Company				Guarantor				Non-Guarantor
		(Parent)				Subsidiaries				Subsidiaries
	Three month period ended March 31, 2014	(in thousands)
	Net sales	$	50,109			$	106,454			$	173,800			$	(21,294	)		$	309,069

	Cost of products sold	45,704				77,584				121,890				(21,357		)		223,821

	Gross Profit	4,405				28,870				51,910				63				85,248

	Selling, general and administrative expenses	31,650				22,268				44,103				—				98,021

	Charge related to restructuring activities	1,164				(95		)		1,171				—				2,240

	Income (loss) from equity investee	10,310				6,931				(36		)		(17,205		)		—

	Interest expense (income)—net	(284		)		865				157				—				738

	Earnings (Loss) from Continuing Operations before Income Taxes	(17,815		)		12,763				6,443				(17,142		)		(15,751		)

	Income taxes	161				—				2,064				—				2,225

	Net Earnings (loss)	$	(17,976	)		$	12,763			$	4,379			$	(17,142	)		$	(17,976	)


	Other Comprehensive Income (Loss), Net of Tax	6,690				(2,290		)		8,955				(6,665		)		6,690


	Comprehensive Income (Loss)	$	(11,286	)		$	10,473			$	13,334			$	(23,807	)		$	(11,286	)



	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)


		The				Combined				Combined				Eliminations				Total
		Company				Guarantor				Non-Guarantor
		(Parent)				Subsidiaries				Subsidiaries
	Three month period ended March 31, 2013	(in thousands)
	Net sales	$	60,909			$	118,436			$	173,925			$	(21,833	)		$	331,437

	Cost of products sold	52,353				85,849				121,705				(22,054		)		237,853

	Gross Profit	8,556				32,587				52,220				221				93,584

	Selling, general and administrative expenses	34,863				23,051				43,977				1,344				103,235

	Charge related to restructuring activities	1,671				—				851				—				2,522

	Income (loss) from equity investee	48,018				5,808				65				(53,891		)		—

	Interest expense (income)—net	(45		)		436				619				—				1,010

	Earnings (Loss) from Continuing Operations before Income Taxes	20,085				14,908				6,838				(55,014		)		(13,183		)

Income taxes (benefit)	(15,096		)		(25		)		7,646				—				(7,475		)

Net Earnings (Loss) from Continuing Operations	35,181				14,933				(808		)		(55,014		)		(5,708		)

Net Earnings from Discontinued Operations	—				40,889				—				—				40,889

Net Earnings (loss)	$	35,181			$	55,822			$	(808	)		$	(55,014	)		$	35,181


Other Comprehensive Income (Loss), Net of Tax	134				(2,186		)		1,787				399				134


Comprehensive Income (Loss)	$	35,315			$	53,636			$	979			$	(54,615	)		$	35,315






CONSOLIDATING CONDENSED BALANCE SHEETS



	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
March 31, 2014	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	2,733			$	212			$	18,315			$	—			$	21,260

Trade receivables, net	62,104				29,569				95,246				—				186,919

Installment receivables, net	—				557				1,033				—				1,590

Inventories, net	21,169				27,076				119,646				(2,548		)		165,343

Deferred income taxes	—				—				2,714				—				2,714

Intercompany advances, net	8,750				521				49,043				(58,314		)		—

Other current assets	8,643				507				32,903				(3,017		)		39,036

Total Current Assets	103,399				58,442				318,900				(63,879		)		416,862

Investment in subsidiaries	1,492,163				458,521				—				(1,950,684		)		—

Intercompany advances, net	974,444				1,639,111				181,460				(2,795,015		)		—

Other Assets	42,655				1,320				2,055				—				46,030

Other Intangibles	543				16,272				44,249				—				61,064

Property and Equipment, net	33,904				16,914				52,927				—				103,745

Goodwill	—				16,660				451,654				—				468,314

Total Assets	$	2,647,108			$	2,207,240			$	1,051,245			$	(4,809,578	)		$	1,096,015

Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	51,340			$	7,834			$	65,268			$	—			$	124,442

Accrued expenses	29,871				16,351				88,140				(3,017		)		131,345

Accrued income taxes	4,220				—				8,051				—				12,271

Intercompany advances, net	45,945				1,956				10,412				(58,313		)		—

Short-term debt and current maturities of long-term obligations	794				8				961				—				1,763

Total Current Liabilities	132,170				26,149				172,832				(61,330		)		269,821

Long-Term Debt	41,811				41				5,342				—				47,194

Other Long-Term Obligations	53,359				—				65,730				—				119,089

Intercompany advances, net	1,759,857				974,811				60,347				(2,795,015		)		—

Total Shareholders’ Equity	659,911				1,206,239				746,994				(1,953,233		)		659,911

Total Liabilities and Shareholders’ Equity	$	2,647,108			$	2,207,240			$	1,051,245			$	(4,809,578	)		$	1,096,015





CONSOLIDATING CONDENSED BALANCE SHEETS


	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
December 31, 2013	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	1,401			$	313			$	28,071			$	—			$	29,785

Trade receivables, net	72,272				28,317				88,033				—				188,622

Installment receivables, net	—				452				1,110				—				1,562

Inventories, net	30,806				27,472				100,444				(3,085		)		155,637

Deferred income taxes	—				—				2,761				—				2,761

Intercompany advances, net	4,179				380				44,292				(48,851		)		—

Other current assets	9,970				568				35,461				(4,827		)		41,172

Total Current Assets	118,628				57,502				300,172				(56,763		)		419,539

Investment in subsidiaries	1,475,156				450,021				—				(1,925,177		)		—

Intercompany advances, net	959,071				1,620,683				179,451				(2,759,205		)		—

Other Assets	42,831				1,061				2,044				—				45,936

Other Intangibles	466				17,109				45,009				—				62,584

Property and Equipment, net	35,169				17,774				53,206				—				106,149

Goodwill	—				16,660				445,566				—				462,226

Total Assets	$	2,631,321			$	2,180,810			$	1,025,448			$	(4,741,145	)		$	1,096,434

Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	42,521			$	7,237			$	66,946			$	—			$	116,704

Accrued expenses	30,314				17,228				90,385				(4,827		)		133,100

Accrued income taxes	5,375				—				6,884				—				12,259

Intercompany advances, net	42,314				2,124				4,413				(48,851		)		—

Short-term debt and current maturities of long-term obligations	13,118				8				976				—				14,102

Total Current Liabilities	133,642				26,597				169,604				(53,678		)		276,165

Long-Term Debt	25,642				61				5,481				—				31,184

Other Long-Term Obligations	53,470				—				64,806				—				118,276

Intercompany advances, net	1,747,758				959,172				52,275				(2,759,205		)		—

Total Shareholders’ Equity	670,809				1,194,980				733,282				(1,928,262		)		670,809

Total Liabilities and Shareholders’ Equity	$	2,631,321			$	2,180,810			$	1,025,448			$	(4,741,145	)		$	1,096,434



CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS



	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
Three month period ended March 31, 2014	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	(1,033	)		$	2,824			$	(8,811	)		$	—			$	(7,020	)

Investing Activities
Purchases of property and equipment	(649		)		(615		)		(2,362		)		—				(3,626		)

Proceeds from sale of property and equipment	—				—				1				—				1

Other long-term assets	(193		)		—				(4		)		—				(197		)

Other	(144		)		—				—				—				(144		)

Net Cash Used for Investing Activities	(986		)		(615		)		(2,365		)		—				(3,966		)

Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	61,547				—				978				—				62,525

Payments on revolving lines of credit and long-term borrowings	(57,885		)		(2,310		)		—				—				(60,195		)

Proceeds from exercise of stock options	85				—				—				—				85

Payment of dividends	(396		)		—				—				—				(396		)

Net Cash Provided (Used) by Financing Activities	3,351				(2,310		)		978				—				2,019

Effect of exchange rate changes on cash	—				—				442				—				442

Decrease in cash and cash equivalents	1,332				(101		)		(9,756		)		—				(8,525		)

Cash and cash equivalents at beginning of year	1,401				313				28,071				—				29,785

Cash and cash equivalents at end of period	$	2,733			$	212			$	18,315			$	—			$	21,260



CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS



	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
Three month period ended March 31, 2013	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	9,297			$	(89,758	)		$	(7,929	)		$	53,087			$	(35,303	)

Investing Activities
Purchases of property and equipment	(2,223		)		(580		)		(1,062		)		—				(3,865		)

Proceeds from sale of property and equipment	—				—				4				—				4

Proceeds from sale of business	—				144,681				—				—				144,681

Other long-term assets	(108		)		—				—				—				(108		)

Other	107,368				(52,956		)		—				(54,431		)		(19		)

Net Cash Provided (Used) for Investing Activities	105,037				91,145				(1,058		)		(54,431		)		140,693

Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	114,762				—				1,188				—				115,950

Payments on revolving lines of credit and long-term borrowings	(232,490		)		(2,206		)		—				—				(234,696		)

Payment of dividends	(396		)		—				(1,344		)		1,344				(396		)

Net Cash Provided (Used) by Financing Activities	(118,124		)		(2,206		)		(156		)		1,344				(119,142		)

Effect of exchange rate changes on cash	—				—				42				—				42

Decrease in cash and cash equivalents	(3,790		)		(819		)		(9,101		)		—				(13,710		)

Cash and cash equivalents at beginning of year	5,774				1,018				31,999				—				38,791

Cash and cash equivalents at end of period	$	1,984			$	199			$	22,898			$	—			$	25,081

Accounting_Policies_Policies

Accounting Policies (Policies)	3 Months Ended
Accounting Policies (Policies)	Mar. 31, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
Principles of Consolidation	Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the Company as of March 31, 2014, the results of its operations for the three months ended March 31, 2014 and changes in its cash flow for the three months ended March 31, 2014 and 2013, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a February 28th quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the Company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	'
Use of Estimates	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.

Receivables_Tables

Receivables (Tables)	3 Months Ended
	Mar. 31, 2014
Receivables [Abstract]	'
Installment Receivables [Table Text Block]	'
	Installment receivables consist of the following (in thousands):


		March 31, 2014									December 31, 2013
		Current			Long-			Total			Current			Long-			Total
					Term									Term
	Installment receivables	$	3,217		$	6,164		$	9,381		$	3,242		$	5,677		$	8,919

	Less: Unearned interest	(60		)	—			(60		)	(61		)	—			(61		)

		3,157			6,164			9,321			3,181			5,677			8,858

	Allowance for doubtful accounts	(1,567		)	(4,654		)	(6,221		)	(1,619		)	(4,420		)	(6,039		)
		$	1,590		$	1,510		$	3,100		$	1,562		$	1,257		$	2,819

Schedule of Installment Receivables Allowance for Doubtful Accounts [Table Text Block]	'
	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):


		Three Months Ended March 31, 2014			Year Ended December 31, 2013
	Balance as of beginning of period	$	6,039		$	3,823

	Current period provision	322			3,457

	Direct write-offs charged against the allowance	(140		)	(1,241		)
	Balance as of end of period	$	6,221		$	6,039

Schedule of Installment Receivables by Class [Table Text Block]	'
	Installment receivables by class as of March 31, 2014 consist of the following (in thousands):


		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	8,014		$	8,014		$	6,136		$	—

	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,282			1,222			—			20

	Impaired Installment receivables with a related allowance recorded	85			85			85			—

	Total Canadian Installment Receivables	$	1,367		$	1,307		$	85		$	20

	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,282			1,222			—			20

	Impaired Installment receivables with a related allowance recorded	8,099			8,099			6,221			—

	Total Installment Receivables	$	9,381		$	9,321		$	6,221		$	20


	Installment receivables by class as of December 31, 2013 consist of the following (in thousands):


		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	7,464		$	7,464		$	5,951		$	—

	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,367			1,306			—			101

	Impaired Installment receivables with a related allowance recorded	88			88			88			—

	Total Canadian Installment Receivables	$	1,455		$	1,394		$	88		$	101

	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,367			1,306			—			101

	Impaired Installment receivables with a related allowance recorded	7,552			7,552			6,039			—

	Total Installment Receivables	$	8,919		$	8,858		$	6,039		$	101

Schedule of Aging of Installment Receivables [Table Text Block]	'
	The aging of the Company’s installment receivables was as follows (in thousands):


		March 31, 2014									31-Dec-13
		Total			U.S.			Canada			Total			U.S.			Canada
	Current	$	1,242		$	—		$	1,242		$	1,338		$	—		$	1,338

	0-30 Days Past Due	9			—			9			7			—			7

	31-60 Days Past Due	11			—			11			—			—			—

	61-90 Days Past Due	1			—			1			—			—			—

	90+ Days Past Due	8,118			8,014			104			7,574			7,464			110

		$	9,381		$	8,014		$	1,367		$	8,919		$	7,464		$	1,455

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory, Net [Abstract]	'
Inventories [Table Text Block]	'
	Inventories consist of the following (in thousands):


		31-Mar-14		31-Dec-13
	Finished goods	$	83,759	$	77,909

	Raw materials	68,590		63,123

	Work in process	12,994		14,605

		$	165,343	$	155,637

Other_Current_Assets_Tables

Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Other Current Assets [Abstract]	'
Schedule of Other Assets [Table Text Block]	'
	Other current assets consist of the following (in thousands):


		March 31, 2014		December 31, 2013
	Value added tax receivables	$	20,176	$	19,699

	Recoverable income taxes	1,644		2,465

	Derivatives (foreign currency forward contracts)	599		789

	Prepaid insurance	3,652		4,556

	Prepaids and other current assets	12,965		13,663

		$	39,036	$	41,172

Other_LongTerm_Assets_Tables

Other Long-Term Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Schedule of Other Assets, Noncurrent [Table Text Block]	'
	Other long-term assets consist of the following (in thousands):


		March 31, 2014		December 31, 2013
	Cash surrender value of life insurance policies	$	36,887	$	36,522

	Deferred Financing Fees	597		1,096

	Investments	990		998

	Long-term installment receivables	1,510		1,257

	Long-term deferred taxes	4,741		4,741

	Other	1,305		1,322

		$	46,030	$	45,936

Property_And_Equipment_Tables

Property And Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and Equipment

	Property and equipment consist of the following (in thousands):


		March 31, 2014			December 31, 2013
	Machinery and equipment	$	363,045		$	358,061

	Land, buildings and improvements	92,169			91,389

	Furniture and fixtures	13,183			12,774

	Leasehold improvements	15,302			14,931

		483,699			477,155

	Less allowance for depreciation	(379,954		)	(371,006		)
		$	103,745		$	106,149

Other_Intangibles_Tables

Other Intangibles (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Definite and Indefinite Lived Intangible Assets [Table Text Block]	'
	The Company's intangibles consist of the following (in thousands):



		March 31, 2014				December 31, 2013
		Historical		Accumulated		Historical		Accumulated
		Cost		Amortization		Cost		Amortization
	Customer Lists	$	92,408	$	66,592	$	92,637	$	65,158

	Trademarks	32,178		—		31,944		—

	License Agreements	1,382		1,382		1,393		1,393

	Developed Technology	10,028		6,621		9,916		6,390

	Patents	6,261		5,657		6,107		5,568

	Other	7,163		8,104		7,407		8,311

		$	149,420	$	88,356	$	149,404	$	86,820

Current_Liabilities_Tables

Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of accruals for the following (in thousands):


		March 31, 2014		December 31, 2013
	Salaries and wages	$	40,019	$	40,252

	Taxes other than income taxes, primarily Value Added Taxes	21,827		24,525

	Warranty cost	27,540		27,393

	Freight	7,372		7,636

	Professional	7,393		6,516

	Product liability, current portion	3,403		3,183

	Rebates	1,957		1,681

	Insurance	2,535		2,549

	Interest	842		1,041

	Derivative liabilities	2,321		1,212

	Severance	3,755		3,986

	Other items, principally trade accruals	12,381		13,126

		$	131,345	$	133,100

Warrany_Costs_Tables

Warrany Costs (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities, Current [Abstract]	'
Accrued Warranty Costs [Table Text Block]	'
	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):



	Balance as of January 1, 2014	$	27,393

	Warranties provided during the period	3,119

	Settlements made during the period	(5,594		)
	Changes in liability for pre-existing warranties during the period, including expirations	2,622

	Balance as of March 31, 2014	$	27,540

LongTerm_Debt_Tables

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2014
Line of Credit Facility [Line Items]	'
Schedule of Line of Credit Facilities [Table Text Block]	'
	An increase in the maximum leverage ratio for the first three quarters of 2014, with quarterly ratios as described in the following table:


	Fiscal Quarter Ending	Maximum Leverage Ratio
	31-Mar-14	4.75		to	1

	30-Jun-14	4.5		to	1

	30-Sep-14	4		to	1

	December 31, 2014 and thereafter	3.5		to	1

	The quarterly minimum interest coverage ratio remains 3.50 to 1.00 in the Amended and Restated Credit Agreement.
Schedule of Debt [Table Text Block]	'
	The liability components of the Company’s convertible debt consist of the following (in thousands):


		March 31, 2014				December 31, 2013
	Principal amount of liability component	$	13,350			$	13,350

	Unamortized discount	(2,539		)		(2,709		)
	Net carrying amount of liability component	$	10,811			$	10,641

Schedule of Long-term Debt Instruments [Table Text Block]	'
	Debt consists of the following (in thousands):


		March 31, 2014				December 31, 2013
	Senior secured revolving credit facility, due in October 2015	$	31,794			$	28,109

	Convertible senior subordinated debentures at 4.125%, due in February 2027	10,811				10,641

	Other notes and lease obligations	6,352				6,536

		48,957				45,286

	Less current maturities of long-term debt	(1,763		)		(14,102		)
		$	47,194			$	31,184

Shareholders_Equity_Transactio1

Shareholders' Equity Transactions (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The amount of amount of stock-based compensation expense recognized under the provisions of Compensation-Stock Compensation, ASC 718 was as follows (in thousands):


		For the Three Months Ended March 31,
		2014				2013
	Stock-based compensation expense recognized as part of selling, general and administrative expense	$	699			$	1,160

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes information about stock option activity for the three months ended March 31, 2014:


		March 31, 2014				Weighted
						Average
						Exercise
						Price
	Options outstanding at January 1, 2014	4,533,782				$	23.86

	Granted	—				—

	Exercised	(5,411		)		15.75

	Canceled	(109,302		)		28.13

	Options outstanding at March 31, 2014	4,419,069				$	23.97

	Options exercise price range at March 31, 2014	$ 12.42 to

		$	47.8

	Options exercisable at March 31, 2014	2,967,156

	Shares available for grant at March 31, 2014*	3,625,869

Schedule of Share-based Compensation, Stock Options Outstanding [Table Text Block]	'
	The following table summarizes information about stock options outstanding at March 31, 2014:


		Options Outstanding							Options Exercisable
	Exercise Prices	Number			Weighted Average		Weighted Average		Number	Weighted Average
		Outstanding			Remaining		Exercise Price		Exercisable	Exercise Price
		At 3/31/14			Contractual Life (Years)				At 3/31/14
	$ 12.42 – $15.00	1,256,124			7.9		$	13.95	461,239	$	13.78

	$ 15.01 – $25.00	1,563,747			4.4		22.52		1,419,474	22.38

	$ 25.01 – $35.00	912,383			4.5		25.73		893,223	25.71

	$ 35.01 – $47.80	686,815			0.3		43.23		667,740	43.22

	Total	4,419,069			4.8		$	23.97	3,441,676	$	26.13

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'


		Foreign Currency			Long-Term Notes			Defined Benefit Plans			Derivatives			Total
	31-Dec-13	$	143,845		$	(12,566	)	$	(5,414	)	$	(709	)	$	125,156

	OCI before reclassifications	6,103			545			484			(626		)	6,506

	Amount reclassified from accumulated OCI	—			—			58			126			184

	Net current-period OCI	6,103			545			542			(500		)	6,690

	31-Mar-14	$	149,948		$	(12,021	)	$	(4,872	)	$	(1,209	)	$	131,846

	Changes in OCI during the three months ended March 31, 2013 were as follows (in thousands):


		Foreign Currency			Long-Term Notes			Defined Benefit Plans			Derivatives			Total
	December 31, 2012	$	117,465		$	2,845		$	(6,785	)	$	(782	)	$	112,743

	OCI before reclassifications	194			(1,692		)	123			1,243			(132		)

	Amount reclassified from accumulated OCI	—			—			13			253			266

	Net current-period OCI	194			(1,692		)	136			1,496			134

	March 31, 2013	$	117,659		$	1,153		$	(6,649	)	$	714		$	112,877

Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'
	Reclassifications out of accumulated OCI for the three months ended March 31, 2014 and March 31, 2013 were as follows (in thousands):


		Amount reclassified from OCI						Affected line item in the Statement of Comprehensive Income (Loss)
		Three Months Ended
		31-Mar-14			31-Mar-13
	Defined Benefit Plans

	Service and interest costs	$	58		$	15		Selling, General and Administrative

	Tax	—			(2		)	Income Taxes

	Total after tax	$	58		$	13


	Derivatives
	Foreign currency forward contracts hedging sales	$	10		$	(136	)	Net Sales

	Foreign currency forward contracts hedging purchases	133			356			Cost of Products Sold

	Interest rate swaps	—			67			Interest Expense

	Total before tax	143			287

	Tax	(17		)	(34		)	Income Taxes
	Total after tax	$	126		$	253

Charges_Related_To_Restructuri1

Charges Related To Restructuring Activities (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Costs [Table Text Block]	'
	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands):


		Severance				Product Line				Contract				Other				Total
						Discontinuance				Terminations
	December 31, 2010 Balance
	Total	$	—			$	—			$	—			$	—			$	—

	Charges
	NA/HME	4,755				—				—				4				4,759

	IPG	123				—				—				—				123

	Europe	3,288				277				1,788				113				5,466

	Asia/Pacific	186				—				—				—				186

	Total	8,352				277				1,788				117				10,534

	Payments
	NA/HME	(1,663		)		—				—				(4		)		(1,667		)

	IPG	(52		)		—				—				—				(52		)

	Europe	(1,546		)		(277		)		(1,714		)		(113		)		(3,650		)
	Asia/Pacific	(186		)		—				—				—				(186		)

	Total	(3,447		)		(277		)		(1,714		)		(117		)		(5,555		)
	December 31, 2011 Balance
	NA/HME	3,092				—				—				—				3,092

	IPG	71				—				—				—				71

	Europe	1,742				—				74				—				1,816

	Asia/Pacific	—				—				—				—				—

	Total	4,905				—				74				—				4,979

	Charges
	NA/HME	4,242				—				5				—				4,247

	IPG	35				—				—				—				35

	Europe	817				—				53				1,223				2,093

	Asia/Pacific	1,681				491				1,667				1,181				5,020

	Total	6,775				491				1,725				2,404				11,395

	Payments
	NA/HME	(3,587		)		—				(5		)		—				(3,592		)

	IPG	(106		)		—				—				—				(106		)

	Europe	(1,964		)		—				(127		)		(1,223		)		(3,314		)

	Asia/Pacific	(812		)		(340		)		(42		)		(1,175		)		(2,369		)
	Total	(6,469		)		(340		)		(174		)		(2,398		)		(9,381		)
	December 31, 2012 Balance
	NA/HME	3,747				—				—				—				3,747

	IPG	—				—				—				—				—

Europe	595				—				—				—				595

Asia/Pacific	869				151				1,625				6				2,651

Total	5,211				151				1,625				6				6,993





	Severance				Product Line				Contract				Other				Total
					Discontinuance				Terminations
Charges
NA/HME	5,405				—				164				353				5,922

IPG	267				—				—				—				267

Europe	1,640				—				—				—				1,640

Asia/Pacific	970				—				534				3				1,507

Total	8,282				—				698				356				9,336

Payments
NA/HME	(6,347		)		—				(164		)		(353		)		(6,864		)

IPG	(175		)		—				—				—				(175		)

Europe	(1,146		)		—				—				—				(1,146		)

Asia/Pacific	(1,839		)		(151		)		(1,660		)		(9		)		(3,659		)
Total	(9,507		)		(151		)		(1,824		)		(362		)		(11,844		)
December 31, 2013 Balance
NA/HME	2,805				—				—				—				2,805

IPG	92				—				—				—				92

Europe	1,089				—				—				—				1,089

Asia/Pacific	—				—				499				—				499

	3,986				—				499				—				4,485

Charges
NA/HME	803				—				—				—				803

IPG	340				—				—				719				1,059

Europe	378				—				—				—				378

Asia/Pacific	—				—				—				—				—

Total	1,521				—				—				719				2,240

Payments
NA/HME	(1,120		)		—				—				—				(1,120		)

IPG	(35		)		—				—				(719		)		(754		)

Europe	(597		)		—				—				—				(597		)

Asia/Pacific	—				—				(154		)		—				(154		)

Total	(1,752		)		—				(154		)		(719		)		(2,625		)

March 31, 2014 Balance
NA/HME	2,488				—				—				—				2,488

IPG	397				—				—				—				397

Europe	870				—				—				—				870

Asia/Pacific	—				—				345				—				345

	$	3,755			$	—			$	345			$	—			$	4,100

Net_Earnings_Loss_Per_Common_S1

Net Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated.


	(In thousands except per share data)	For the Three Months Ended March 31,
		2014			2013
	Basic
	Average common shares outstanding	32,013			31,902


	Net loss from continuing operations	$	(17,976	)	$	(5,708	)
	Net earnings from discontinued operations	$	—		$	40,889

	Net earnings (loss)	$	(17,976	)	$	35,181


	Net loss per common share from continuing operations	$	(0.56	)	$	(0.18	)
	Net earnings per common share from discontinued operations	$	—		$	1.28

	Net earnings (loss) per common share	$	(0.56	)	$	1.1


	Diluted
	Average common shares outstanding	32,013			31,902

	Shares related to convertible debt	—			—

	Stock options and awards	288			32

	Average common shares assuming dilution	32,301			31,934


	Net loss from continuing operations	$	(17,976	)	$	(5,708	)
	Net earnings from discontinued operations	$	—		$	40,889

	Net earnings (loss)	$	(17,976	)	$	35,181


	Net loss per common share from continuing operations *	$	(0.56	)	$	(0.18	)
	Net earnings per common share from discontinued operations	$	—		$	1.28

	Net earnings (loss) per common share *	$	(0.56	)	$	1.1


	* Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the period in which there was a net loss.

Derivatives_Tables

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	'
	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):


		March 31, 2014						December 31, 2013
		Notional			Unrealized			Notional			Unrealized
		Amount			Net Gain			Amount			Net Gain
					(Loss)						(Loss)
	USD / AUD	$	1,650		$	(54	)	$	—		$	—

	USD / CNY	10,600			(207		)	11,730			(66		)

	USD / CHF	339			(8		)	486			4

	USD / EUR	39,317			(767		)	51,106			(168		)

	USD / GBP	2,132			(85		)	2,686			(45		)

	USD / NZD	1,204			(47		)	—			—

	USD / SEK	1,734			(5		)	2,485			58

	USD / MXP	8,683			174			5,960			102

	EUR / AUD	500			(16		)	—			—

	EUR / CAD	1,326			71			1,710			(1		)

	EUR / CHF	2,322			32			2,654			1

	EUR / DKK	1,096			(3		)	1,382			(5		)

	EUR / GBP	23,440			(601		)	29,614			(501		)

	EUR / SEK	2,790			11			3,432			75

	EUR / NOK	2,480			31			3,135			66

	EUR / NZD	5,679			224			6,959			(111		)

	AUD / CAD	1,323			(18		)	—			—

	AUD / NZD	883			(6		)	—			—

	GBP / CHF	661			(16		)	837			(26		)

	GBP / SEK	1,644			(78		)	2,078			(101		)

	DKK / SEK	3,981			(29		)	5,337			(94		)

	NOK / SEK	2,575			24			3,418			31

		$	116,359		$	(1,373	)	$	135,009		$	(781	)

Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2014 and 2013, respectively, and outstanding were as follows (in thousands USD):


		March 31, 2014						March 31, 2013
		Notional			Gain			Notional			Gain
		Amount			(Loss)			Amount			(Loss)
	AUD / USD	$	2,100		$	(52	)	$	—		$	—

	CAD / USD	5,612			(184		)	24,120			$	(544	)

	CNY / USD	1,482			(40		)	—			—

	EUR / USD	15,138			18			—			—

	CHF / USD	678			1			—			—

	DKK / USD	6,636			13			22,970			(598		)

	NZD / USD	5,000			(86		)	—			—

	EUR / AUD	—			—			1,500			(35		)

	EUR / DKK	5,548			(9		)	—			—

	AUD / EUR	2,106			(6		)	—			—

	AUD / GBP	—			—			2,966			6

		$	44,300		$	(345	)	$	51,556		$	(1,171	)

Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	The fair values of the Company’s derivative instruments were as follows (in thousands):


		March 31, 2014						December 31, 2013
		Assets			Liabilities			Assets			Liabilities
	Derivatives designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	$	568		$	1,941		$	414		$	1,195

	Interest rate swap contracts	—			4			—			12

	Derivatives not designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	31			376			375			5

	Total derivatives	$	599		$	2,321		$	789		$	1,212

Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]	'
	The effect of derivative instruments on the Statement of Comprehensive Income (Loss) and Other Comprehensive Income (OCI) was as follows (in thousands):


	Derivatives in ASC 815 cash flow hedge	Amount of Gain			Amount of Gain (Loss)			Amount of Gain (Loss)
	relationships	(Loss) Recognized in OCI on Derivatives			Reclassified from			Recognized in Income on
		(Effective Portion)			Accumulated OCI into			Derivatives (Ineffective Portion
					Income (Effective			and Amount Excluded from
					Portion)			Effectiveness Testing)
	Three months ended March 31, 2014
	Foreign currency forward exchange contracts	$	(382	)	$	(126	)	$	—

	Interest rate swap contracts	8			—			—

		$	(374	)	$	(126	)	$	—

	Three months ended March 31, 2013
	Foreign currency forward exchange contracts	$	1,601		$	(220	)	$	57

	Interest rate swap contracts	263			(67		)	—

		$	1,864		$	(287	)	$	57


	Derivatives not designated as hedging							Amount of Gain (Loss)
	instruments under ASC 815							Recognized in Income on Derivatives
	Three months ended March 31, 2014
	Foreign currency forward exchange contracts							$	(345	)
	Three months ended March 31, 2013
	Foreign currency forward exchange contracts							$	(1,171	)

Fair_Values_of_Financial_Instr

Fair Values of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following table provides a summary of the Company’s assets and liabilities that are measured on a recurring basis (in thousands).


					Basis for Fair Value Measurements at Reporting Date
					Quoted Prices in Active			Significant				Significant
					Markets for Identical			Other				Other
					Assets / (Liabilities)			Observable				Unobservable
								Inputs				Inputs
		Total			Level I			Level II				Level III
	31-Mar-14
	Forward Exchange Contracts—net	$	(1,718	)	—			$	(1,718	)		—

	Interest Rate Swap Agreements—net	(4		)	—			(4		)		—

	31-Dec-13
	Forward Exchange Contracts—net	$	(411	)	—			$	(411	)		—

	Interest Rate Swap Agreements—net	(12		)	—			(12		)		—

Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The carrying values and fair values of the Company’s financial instruments are as follows (in thousands):


		March 31, 2014							December 31, 2013
		Carrying			Fair Value				Carrying				Fair Value
		Value							Value
	Cash and cash equivalents	$	21,260		$	21,260			$	29,785			$	29,785

	Other investments	990			990				998				998

	Installment receivables, net of reserves	3,100			3,100				2,819				2,819

	Long-term debt (including current maturities of long-term debt)	(48,957		)	(48,471		)		(45,286		)		(46,124		)
	Forward contracts in Other Current Assets	599			599				789				789

	Forward contracts in Accrued Expenses	(2,317		)	(2,317		)		(1,200		)		(1,200		)
	Interest rate swap agreements in Accrued Expenses	(4		)	(4		)		(12		)		(12		)

Business_Segments_Tables

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The information by segment is as follows (in thousands):


		For the Three Months Ended
		March 31, 2014			March 31, 2013
	Revenues from external customers
	North America/HME	$	129,110		$	151,882

	Institutional Products Group	25,136			29,224

	Europe	142,768			137,634

	Asia/Pacific	12,055			12,697

	Consolidated	$	309,069		$	331,437

	Intersegment revenues
	North America/HME	$	18,673		$	18,836

	Institutional Products Group	1,573			1,107

	Europe	1,682			1,953

	Asia/Pacific	6,192			6,882

	Consolidated	$	28,120		$	28,778

	Restructuring charges before income taxes
	North America/HME	$	803		$	1,679

	Institutional Products Group	1,059			188

	Europe	378			115

	Asia/Pacific	—			540

	Consolidated	$	2,240		$	2,522

	Earnings (loss) before income taxes
	North America/HME	$	(16,799	)	$	(11,179	)
	Institutional Products Group	(251		)	474

	Europe	9,246			5,843

	Asia/Pacific	(2,801		)	(2,261		)
	All Other (1)	(5,146		)	(6,060		)
	Consolidated	$	(15,751	)	$	(13,183	)
	________________________

	-1	Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments.

Supplemental_Guarantor_Informa1

Supplemental Guarantor Information Supplemental Guarantor Information (Tables)	3 Months Ended
	Mar. 31, 2014
Supplemental Guarantor Information [Abstract]	'
Condensed Financial Statements [Table Text Block]	'
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)


		The				Combined				Combined				Eliminations				Total
		Company				Guarantor				Non-Guarantor
		(Parent)				Subsidiaries				Subsidiaries
	Three month period ended March 31, 2014	(in thousands)
	Net sales	$	50,109			$	106,454			$	173,800			$	(21,294	)		$	309,069

	Cost of products sold	45,704				77,584				121,890				(21,357		)		223,821

	Gross Profit	4,405				28,870				51,910				63				85,248

	Selling, general and administrative expenses	31,650				22,268				44,103				—				98,021

	Charge related to restructuring activities	1,164				(95		)		1,171				—				2,240

	Income (loss) from equity investee	10,310				6,931				(36		)		(17,205		)		—

	Interest expense (income)—net	(284		)		865				157				—				738

	Earnings (Loss) from Continuing Operations before Income Taxes	(17,815		)		12,763				6,443				(17,142		)		(15,751		)

	Income taxes	161				—				2,064				—				2,225

	Net Earnings (loss)	$	(17,976	)		$	12,763			$	4,379			$	(17,142	)		$	(17,976	)


	Other Comprehensive Income (Loss), Net of Tax	6,690				(2,290		)		8,955				(6,665		)		6,690


	Comprehensive Income (Loss)	$	(11,286	)		$	10,473			$	13,334			$	(23,807	)		$	(11,286	)



	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)


		The				Combined				Combined				Eliminations				Total
		Company				Guarantor				Non-Guarantor
		(Parent)				Subsidiaries				Subsidiaries
	Three month period ended March 31, 2013	(in thousands)
	Net sales	$	60,909			$	118,436			$	173,925			$	(21,833	)		$	331,437

	Cost of products sold	52,353				85,849				121,705				(22,054		)		237,853

	Gross Profit	8,556				32,587				52,220				221				93,584

	Selling, general and administrative expenses	34,863				23,051				43,977				1,344				103,235

	Charge related to restructuring activities	1,671				—				851				—				2,522

	Income (loss) from equity investee	48,018				5,808				65				(53,891		)		—

	Interest expense (income)—net	(45		)		436				619				—				1,010

	Earnings (Loss) from Continuing Operations before Income Taxes	20,085				14,908				6,838				(55,014		)		(13,183		)

	Income taxes (benefit)	(15,096		)		(25		)		7,646				—				(7,475		)

	Net Earnings (Loss) from Continuing Operations	35,181				14,933				(808		)		(55,014		)		(5,708		)

	Net Earnings from Discontinued Operations	—				40,889				—				—				40,889

Net Earnings (loss)	$	35,181			$	55,822			$	(808	)		$	(55,014	)		$	35,181


Other Comprehensive Income (Loss), Net of Tax	134				(2,186		)		1,787				399				134


Comprehensive Income (Loss)	$	35,315			$	53,636			$	979			$	(54,615	)		$	35,315






CONSOLIDATING CONDENSED BALANCE SHEETS



	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
March 31, 2014	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	2,733			$	212			$	18,315			$	—			$	21,260

Trade receivables, net	62,104				29,569				95,246				—				186,919

Installment receivables, net	—				557				1,033				—				1,590

Inventories, net	21,169				27,076				119,646				(2,548		)		165,343

Deferred income taxes	—				—				2,714				—				2,714

Intercompany advances, net	8,750				521				49,043				(58,314		)		—

Other current assets	8,643				507				32,903				(3,017		)		39,036

Total Current Assets	103,399				58,442				318,900				(63,879		)		416,862

Investment in subsidiaries	1,492,163				458,521				—				(1,950,684		)		—

Intercompany advances, net	974,444				1,639,111				181,460				(2,795,015		)		—

Other Assets	42,655				1,320				2,055				—				46,030

Other Intangibles	543				16,272				44,249				—				61,064

Property and Equipment, net	33,904				16,914				52,927				—				103,745

Goodwill	—				16,660				451,654				—				468,314

Total Assets	$	2,647,108			$	2,207,240			$	1,051,245			$	(4,809,578	)		$	1,096,015

Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	51,340			$	7,834			$	65,268			$	—			$	124,442

Accrued expenses	29,871				16,351				88,140				(3,017		)		131,345

Accrued income taxes	4,220				—				8,051				—				12,271

Intercompany advances, net	45,945				1,956				10,412				(58,313		)		—

Short-term debt and current maturities of long-term obligations	794				8				961				—				1,763

Total Current Liabilities	132,170				26,149				172,832				(61,330		)		269,821

Long-Term Debt	41,811				41				5,342				—				47,194

Other Long-Term Obligations	53,359				—				65,730				—				119,089

Intercompany advances, net	1,759,857				974,811				60,347				(2,795,015		)		—

Total Shareholders’ Equity	659,911				1,206,239				746,994				(1,953,233		)		659,911

Total Liabilities and Shareholders’ Equity	$	2,647,108			$	2,207,240			$	1,051,245			$	(4,809,578	)		$	1,096,015





CONSOLIDATING CONDENSED BALANCE SHEETS


	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
December 31, 2013	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	1,401			$	313			$	28,071			$	—			$	29,785

Trade receivables, net	72,272				28,317				88,033				—				188,622

Installment receivables, net	—				452				1,110				—				1,562

Inventories, net	30,806				27,472				100,444				(3,085		)		155,637

Deferred income taxes	—				—				2,761				—				2,761

Intercompany advances, net	4,179				380				44,292				(48,851		)		—

Other current assets	9,970				568				35,461				(4,827		)		41,172

Total Current Assets	118,628				57,502				300,172				(56,763		)		419,539

Investment in subsidiaries	1,475,156				450,021				—				(1,925,177		)		—

Intercompany advances, net	959,071				1,620,683				179,451				(2,759,205		)		—

Other Assets	42,831				1,061				2,044				—				45,936

Other Intangibles	466				17,109				45,009				—				62,584

Property and Equipment, net	35,169				17,774				53,206				—				106,149

Goodwill	—				16,660				445,566				—				462,226

Total Assets	$	2,631,321			$	2,180,810			$	1,025,448			$	(4,741,145	)		$	1,096,434

Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	42,521			$	7,237			$	66,946			$	—			$	116,704

Accrued expenses	30,314				17,228				90,385				(4,827		)		133,100

Accrued income taxes	5,375				—				6,884				—				12,259

Intercompany advances, net	42,314				2,124				4,413				(48,851		)		—

Short-term debt and current maturities of long-term obligations	13,118				8				976				—				14,102

Total Current Liabilities	133,642				26,597				169,604				(53,678		)		276,165

Long-Term Debt	25,642				61				5,481				—				31,184

Other Long-Term Obligations	53,470				—				64,806				—				118,276

Intercompany advances, net	1,747,758				959,172				52,275				(2,759,205		)		—

Total Shareholders’ Equity	670,809				1,194,980				733,282				(1,928,262		)		670,809

Total Liabilities and Shareholders’ Equity	$	2,631,321			$	2,180,810			$	1,025,448			$	(4,741,145	)		$	1,096,434



CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS



	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
Three month period ended March 31, 2014	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	(1,033	)		$	2,824			$	(8,811	)		$	—			$	(7,020	)

Investing Activities
Purchases of property and equipment	(649		)		(615		)		(2,362		)		—				(3,626		)

Proceeds from sale of property and equipment	—				—				1				—				1

Other long-term assets	(193		)		—				(4		)		—				(197		)

Other	(144		)		—				—				—				(144		)

Net Cash Used for Investing Activities	(986		)		(615		)		(2,365		)		—				(3,966		)

Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	61,547				—				978				—				62,525

Payments on revolving lines of credit and long-term borrowings	(57,885		)		(2,310		)		—				—				(60,195		)

Proceeds from exercise of stock options	85				—				—				—				85

Payment of dividends	(396		)		—				—				—				(396		)

Net Cash Provided (Used) by Financing Activities	3,351				(2,310		)		978				—				2,019

Effect of exchange rate changes on cash	—				—				442				—				442

Decrease in cash and cash equivalents	1,332				(101		)		(9,756		)		—				(8,525		)

Cash and cash equivalents at beginning of year	1,401				313				28,071				—				29,785

Cash and cash equivalents at end of period	$	2,733			$	212			$	18,315			$	—			$	21,260



CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS



	The				Combined				Combined				Eliminations				Total
	Company				Guarantor				Non-Guarantor
	(Parent)				Subsidiaries				Subsidiaries
Three month period ended March 31, 2013	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	9,297			$	(89,758	)		$	(7,929	)		$	53,087			$	(35,303	)

Investing Activities
Purchases of property and equipment	(2,223		)		(580		)		(1,062		)		—				(3,865		)

Proceeds from sale of property and equipment	—				—				4				—				4

Proceeds from sale of business	—				144,681				—				—				144,681

Other long-term assets	(108		)		—				—				—				(108		)

Other	107,368				(52,956		)		—				(54,431		)		(19		)

Net Cash Provided (Used) for Investing Activities	105,037				91,145				(1,058		)		(54,431		)		140,693

Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	114,762				—				1,188				—				115,950

Payments on revolving lines of credit and long-term borrowings	(232,490		)		(2,206		)		—				—				(234,696		)

Payment of dividends	(396		)		—				(1,344		)		1,344				(396		)

Net Cash Provided (Used) by Financing Activities	(118,124		)		(2,206		)		(156		)		1,344				(119,142		)

Effect of exchange rate changes on cash	—				—				42				—				42

Decrease in cash and cash equivalents	(3,790		)		(819		)		(9,101		)		—				(13,710		)

Cash and cash equivalents at beginning of year	5,774				1,018				31,999				—				38,791

Cash and cash equivalents at end of period	$	1,984			$	199			$	22,898			$	—			$	25,081

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	0 Months Ended	3 Months Ended		0 Months Ended		3 Months Ended		0 Months Ended	3 Months Ended
	Dec. 21, 2012	Mar. 31, 2014	Mar. 31, 2013	Jan. 18, 2013	Dec. 21, 2012	Mar. 31, 2014	Mar. 31, 2013	Aug. 06, 2013	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013
	Dec. 21, 2012	Mar. 31, 2014	Mar. 31, 2013	ISG [Member]	ISG [Member]	ISG [Member]	ISG [Member]	Champion [Member]	Champion [Member]	Champion [Member]	Champion [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Agreement to Sell Operations Date	31-Dec-13	'	'	'	21-Dec-12	'	'	'	'	'	'
Disposal Date	'	'	'	18-Jan-13	'	'	'	6-Aug-13	'	'	'
Proceeds from Divestiture of Businesses	'	'	'	'	'	'	$150,800,000	'	$45,000,000	'	'
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	'	0	59,402,000	'	'	'	-59,402,000	'	'	-22,761,000	'
Disposal Group, Expenses Related to Sale of Business	'	'	'	'	'	5,350,000	'	'	2,130,000	'	'
Disposal Group, Expenses Related to Sale of Business, cash paid	'	'	'	'	'	5,002,000	'	'	1,519,000	'	'
Net Sales from Discontinued Operations	'	'	'	'	'	'	18,498,000	'	'	'	6,179,000
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	'	'	'	'	'	'	402,000	'	'	'	1,200,000
Interest Expense Allocation from Continuing to Discontinuing Operations	'	'	'	'	'	'	'	'	'	'	$186,000

Receivables_Narrative_Details

Receivables Narrative (Details) (USD $)	3 Months Ended
Receivables Narrative (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Allowance for Doubtful Accounts Receivable	$16,912,000	$17,715,000
Number of Missed Payments before Delinquent	3	'
Typical Financing Period	'12 months	'
Credit amount requiring additional analysis	250,000	'
Average Period of Adjudication	'18 months	'
Installment receivable purchased from DLL	$1,212,000	'

Receivables_Details

Receivables (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Total Installment Receivables	$9,381	$8,919	'
Installment Receivables, Net of Unearned Interest	9,321	8,858	'
Allowance for doubtful accounts	-6,221	-6,039	'
Installment receivables, net	1,590	1,562	'
Installment receivables, net, long-term	1,510	1,257	'
Installment Receivables [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Installment Receivables, Current	3,217	3,242	'
Installment Receivables, Long-Term	6,164	5,677	'
Total Installment Receivables	9,381	8,919	'
Unearned Interest, Current	-60	-61	'
Unearned Interest, Noncurrent	0	0	'
Total Unearned Interest	-60	-61	'
Installment Receivables Net of Unearned Interest Current	3,157	3,181	'
Installment Receivables Net of Unearned Interest Noncurrent	6,164	5,677	'
Installment Receivables, Net of Unearned Interest	9,321	8,858	'
Allowance for doubtful accounts, current	-1,567	-1,619	'
Allowance for doubtful accounts, long-term	-4,654	-4,420	'
Allowance for doubtful accounts	-6,221	-6,039	-3,823
Installment receivables, net	1,590	1,562	'
Installment receivables, net, long-term	1,510	1,257	'
Installment receivables, net	$3,100	$2,819	'

Receivables_Rollforward_of_All

Receivables Rollforward of Allowance for Doubtful Accounts (Details) (USD $)	3 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
	Mar. 31, 2014	Mar. 31, 2013	Installment Receivables [Member]	Installment Receivables [Member]
Allowance for Doubtful Accounts [Roll Forward]	'	'	'	'
Balance as of January 1	$6,039	'	$6,039	$3,823
Current period provision	663	768	322	3,457
Direct write-offs charged against the allowance	'	'	-140	-1,241
Balance as of December 31	$6,221	'	$6,221	$6,039

Receivables_Installment_Receiv

Receivables Installment Receivables by Class (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	$9,381	$8,919
Unpaid Principal Balance	9,321	8,858
Related Allowance for Doubtful Accounts	6,221	6,039
Interest Income Recognized	20	101
CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,367	1,455
Unpaid Principal Balance	1,307	1,394
Related Allowance for Doubtful Accounts	85	88
Interest Income Recognized	20	101
Impaired Installment Receivables with Related Allowance [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	8,099	7,552
Unpaid Principal Balance	8,099	7,552
Related Allowance for Doubtful Accounts	6,221	6,039
Interest Income Recognized	0	0
Impaired Installment Receivables with Related Allowance [Member] \| U.S.	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	8,014	7,464
Unpaid Principal Balance	8,014	7,464
Related Allowance for Doubtful Accounts	6,136	5,951
Interest Income Recognized	0	0
Impaired Installment Receivables with Related Allowance [Member] \| CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	85	88
Unpaid Principal Balance	85	88
Related Allowance for Doubtful Accounts	85	88
Interest Income Recognized	0	0
Installment Receivables [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,282	1,367
Unpaid Principal Balance	1,222	1,306
Related Allowance for Doubtful Accounts	0	0
Interest Income Recognized	20	101
Installment Receivables [Member] \| CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,282	1,367
Unpaid Principal Balance	1,222	1,306
Related Allowance for Doubtful Accounts	0	0
Interest Income Recognized	$20	$101

Receivables_Aging_of_Installme

Receivables Aging of Installment Receivables (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	$1,242	$1,338
0-30 Days Past Due	9	7
31-60 Days Past Due	11	0
61-90 Days Past Due	1	0
Greater than 90 Days Past Due	8,118	7,574
Total Installment Receivables Past Due	9,381	8,919
U.S.	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	0	0
0-30 Days Past Due	0	0
31-60 Days Past Due	0	0
61-90 Days Past Due	0	0
Greater than 90 Days Past Due	8,014	7,464
Total Installment Receivables Past Due	8,014	7,464
CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	1,242	1,338
0-30 Days Past Due	9	7
31-60 Days Past Due	11	0
61-90 Days Past Due	1	0
Greater than 90 Days Past Due	104	110
Total Installment Receivables Past Due	$1,367	$1,455

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Inventory, Net [Abstract]	'	'
Finished goods	$83,759	$77,909
Raw materials	68,590	63,123
Work in process	12,994	14,605
Inventory, Net	$165,343	$155,637

Other_Current_Assets_Details

Other Current Assets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Other Current Assets [Abstract]	'	'
Value Added Tax Receivables	$20,176	$19,699
Recoverable Income Taxes	1,644	2,465
Derivative Assets	599	789
Prepaid Insurance	3,652	4,556
Prepaid Expense and Other Current Assets	12,965	13,663
Other current assets	$39,036	$41,172

Other_LongTerm_Assets_Details

Other Long-Term Assets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Text Block [Abstract]	'	'
Cash Surrender Value of Life Insurance	$36,887	$36,522
Deferred Financing Fees	597	1,096
Investments	990	998
Installment receivables, net, long-term	1,510	1,257
Long-term Deferred Taxes	4,741	4,741
Prepaid Expense and Other Assets, Noncurrent	1,305	1,322
Other Assets	$46,030	$45,936

Property_And_Equipment_Details

Property And Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$483,699	$477,155
Less allowance for depreciation	-379,954	-371,006
Property and Equipment, net	103,745	106,149
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	363,045	358,061
Land, Buildings and Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	92,169	91,389
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	13,183	12,774
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$15,302	$14,931

Other_Intangibles_Narrative_De

Other Intangibles Narrative (Details) (USD $)	3 Months Ended			3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
	Mar. 31, 2014	Trademarks [Member]	Trademarks [Member]	Minimum [Member]	Maximum [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Indefinite-lived Intangible Assets	'	$32,178,000	$31,944,000	'	'
Finite-Lived Intangible Assets, Useful Life, Minimum	'	'	'	'1 year	'11 years
Finite-Lived Intangible Assets, Average Useful Life	'6 years	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense	$2,162,000	'	'	'	'

Other_Intangibles_Details

Other Intangibles (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	$149,420,000	$149,404,000
Finite-Lived Intangible Assets, Accumulated Amortization	88,356,000	86,820,000
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	92,408,000	92,637,000
Finite-Lived Intangible Assets, Accumulated Amortization	66,592,000	65,158,000
Licensing Agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	1,382,000	1,393,000
Finite-Lived Intangible Assets, Accumulated Amortization	1,382,000	1,393,000
Developed Technology Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	10,028,000	9,916,000
Finite-Lived Intangible Assets, Accumulated Amortization	6,621,000	6,390,000
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	6,261,000	6,107,000
Finite-Lived Intangible Assets, Accumulated Amortization	5,657,000	5,568,000
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	7,163,000	7,407,000
Finite-Lived Intangible Assets, Accumulated Amortization	8,104,000	8,311,000
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-lived Intangible Assets	$32,178,000	$31,944,000

Other_Intangibles_FiniteLived_

Other Intangibles Finite-Lived Intangible Asset Future Amortization Expense (Details) (USD $)	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]	'
Future Amortization Expense, Entire Fiscal Year	$8,436,000
Future Amortization Expense, Year One	7,260,000
Future Amortization Expense, Year Two	5,787,000
Future Amortization Expense, Year Three	2,281,000
Future Amortization Expense, Year Four	2,272,000
Future Amortization Expense, Year Five	$2,266,000

Current_Liabilities_Details

Current Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]	'	'
Salaries and Wages	$40,019	$40,252
Taxes other than income taxes, primarily Value Added Taxes	21,827	24,525
Product Warranty Accrual, Current	27,540	27,393
Freight	7,372	7,636
Professional	7,393	6,516
Product Liability, Current Portion	3,403	3,183
Rebates	1,957	1,681
Insurance	2,535	2,549
Interest	842	1,041
Derivative Liabilities	2,321	1,212
Severance	3,755	3,986
Other items, principally trade accruals	12,381	13,126
Accrued expenses	$131,345	$133,100

Warrany_Costs_Warranty_Schedul

Warrany Costs Warranty Schedule (Details) (USD $)	3 Months Ended
Warrany Costs Warranty Schedule (Details) (USD $)	Mar. 31, 2014
Product Liability Contingency [Line Items]	'
Loss Contingency Accrual, at Carrying Value	$2,237,000
Balance at Beginning of Period	27,393,000
Warranties provided during the period	3,119,000
Settlements made during the period	-5,594,000
Changes in liability for pre-existing warranties during the period, including expirations	2,622,000
Balance at of End of Period	27,540,000
Loss Contingency Accrual Carrying Value, Net of Tax	2,100,000
NA/HME [Member]	'
Product Liability Contingency [Line Items]	'
Loss Contingency Accrual, at Carrying Value	1,171,000
Asia Pacific [Member]	'
Product Liability Contingency [Line Items]	'
Loss Contingency Accrual, at Carrying Value	$929,000

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)

3 Months Ended

Mar. 31, 2014

Jan. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Jan. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

28-May-13

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Line of Credit [Member]

Convertible Subordinated Debt [Member]

Notes Payable, Other Payables [Member]

Maximum [Member]

Minimum [Member]

Senior Secured Revolving Credit Facility October 2015 [Member]

Convertible Senior Subordinated Debentures February 2027 [Member]

Other Notes and Lease Obligations [Member]

Line of Credit [Member]

Senior Secured Revolving Credit Facility October 2015 [Member]

Line of Credit [Member]

Senior Secured Revolving Credit Facility October 2015 [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$100,000,000

$250,000,000

Reductions in Capital Expenditures

25,000,000

Increase in Basis Points in the Margin Applicable to Determing the Interest Rate on New Debt

Payments of Debt Issuance Costs

351,000

Ratio of Earnings before Interest Taxes Depreciation and Amortization to Interest Expense

3.5

Future One-Time Cash Restructuring Charges Added Back to EBITDA

20,000,000

Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization

3.5

4.5

4.75

Long-term Debt

48,957,000

45,286,000

31,794,000

28,109,000

10,811,000

10,641,000

6,352,000

6,536,000

Long-term Debt, Current Maturities

-1,763,000

-14,102,000

Long-term Debt, Excluding Current Maturities

47,194,000

31,184,000

Write off of Deferred Debt Issuance Cost

$1,070,000

LongTerm_Debt_Line_of_Credit_D

Long-Term Debt Line of Credit (Details) (USD $)

0 Months Ended

3 Months Ended

30-May-13

Mar. 31, 2014

Jan. 31, 2014

Mar. 31, 2014

Jan. 31, 2014

Mar. 31, 2014

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

28-May-13

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Line of Credit [Member]

Convertible Subordinated Debt [Member]

Maximum [Member]

Minimum [Member]

Senior Secured Revolving Credit Facility October 2015 [Member]

Convertible Senior Subordinated Debentures February 2027 [Member]

Line of Credit [Member]

Senior Secured Revolving Credit Facility October 2015 [Member]

Line of Credit [Member]

Senior Secured Revolving Credit Facility October 2015 [Member]

Debt Instrument [Line Items]

Debt Amendment Date

31-Jan-14

Line of Credit Facility, Maximum Borrowing Capacity

$100,000,000

$250,000,000

Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization

3.5

4.5

4.75

Ratio of Earnings before Interest Taxes Depreciation and Amortization to Interest Expense

3.5

Future One-Time Cash Restructuring Charges Added Back to EBITDA

20,000,000

Increase in Basis Points in the Margin Applicable to Determing the Interest Rate on New Debt

Payments of Debt Issuance Costs

351,000

Write off of Deferred Debt Issuance Cost

$1,070,000

LongTerm_Debt_Convertible_Debt

Long-Term Debt Convertible Debt (Details) (Convertible Subordinated Debt [Member], Convertible Senior Subordinated Debentures February 2027 [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Feb. 17, 2007
Convertible Subordinated Debt [Member] \| Convertible Senior Subordinated Debentures February 2027 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt Instrument, Unamortized Discount	($2,539,000)	($2,709,000)	'
Principal Amount	'	'	$135,000,000
Interest Rate	4.13%	'	'

LongTerm_Debt_Interest_Rate_Sw

Long-Term Debt Interest Rate Swaps (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Derivative [Line Items]	'	'
Long-term Debt, Weighted Average Interest Rate	2.41%	2.39%
Interest Rate Derivative, April 2014, .54% [Member] \| Interest Rate Swap [Member]	'	'
Derivative [Line Items]	'	'
Notional Amount	12,000,000	'
Derivative, Fixed Interest Rate on LIBOR Component	0.54%	'
Derivative, Effective Aggregate Interest Rate	2.79%	'

LongTerm_Debt_Components_of_Co

Long-Term Debt Components of Convertible Debt (Details) (Convertible Subordinated Debt [Member], Convertible Senior Subordinated Debentures February 2027 [Member], USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Convertible Subordinated Debt [Member] \| Convertible Senior Subordinated Debentures February 2027 [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal amount of liability component	$13,350	$13,350
Debt Instrument, Unamortized Discount	-2,539	-2,709
Convertible Debt	$10,811	$10,641

Shareholders_Equity_Transactio2

Shareholders' Equity Transactions Narrative (Details) (USD $)	0 Months Ended			3 Months Ended
	21-May-13	16-May-13	Mar. 27, 2013	Mar. 31, 2014		Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'10 years		'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	4,460,337	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	'	'	'	0		'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	21-May-13	'	'	'		'
Annual Shareholder Meeting Date	'	16-May-13	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Adoption date	'	'	27-Mar-13	'		'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	'	'	$17,457,000		'
Allocated Share-based Compensation Expense	'	'	'	699,000		1,160,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'	'2 years		'
Restricted Stock [Member]	'	'	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity	'	'	'	376,068		'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'3 years		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	'	'	'	598,137		'
Allocated Share Based Compensation Expense Recognized Weighted Average Period	'	'	'	'1 year 6 months		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	'	188,034		'
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited	'	'	'	7,575		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vesting Entirety Date	'	'	'	15-May-17		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	'	$20.05		'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	'	'	7,230,000		'
Allocated Share-based Compensation Expense	'	'	'	115,000		'
Stock Options [Member]	'	'	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'4 years		'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	3,625,869	[1]	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	'	'	'	7,217,000		'
Employee Service Share-based Compensation, Term	'	'	'	'10 years		'
Allocated Share-based Compensation Expense	'	'	'	530,000		'
Performance Shares [Member]	'	'	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity	'	'	'	458,400		'
Allocated Share Based Compensation Expense Recognized Weighted Average Period	'	'	'	'1 year 6 months		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	'	152,800		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	'	$20.05		'
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	'	'	'	'3 years		'
Period of Performance Award Measurement, Beginning	'	'	'	1-Jan-16		'
Period of Performance Award Measurement, Ending	'	'	'	31-Dec-16		'
Level of Performance Award Achievement, Minimum	'	'	'	0.00%		'
Level of Performance Award Achievement, Maximum	'	'	'	150.00%		'
Level of Performance Award Achievement, Target	'	'	'	100.00%		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested	'	'	'	3,010,000		'
Allocated Share-based Compensation Expense	'	'	'	$54,000		'

[1]	*Shares available for grant as of MarchB 31, 2014 reduced by net restricted stock and restricted stock unit award and performance share and performance share unit award activity of 376,068 shares and 458,400

Shareholders_Equity_Transactio3

Shareholders' Equity Transactions Options Activity (Details) (USD $)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013	16-May-13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'
Allocated Share-based Compensation Expense	$699,000		$1,160,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'	'
Options outstanding at beginning of period	4,533,782		'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	0		'	'
Excercised	-5,411		'	'
Canceled	-109,302		'	'
Options outstanding at end of period	4,419,069		'	'
Granted Weighted Average Exercise Price	$0		'	'
Options outstanding at beginning of period Weighted Average Exercise Price	$23.86		'	'
Excercised Weighted Average Exercise Price	$0		'	'
Canceled Weighted Average Exercise Price	$28.13		'	'
Options outstanding at end of period Weighted Average Exercise Price	$23.97		'	'
Options exercise price range at end of period, Lower Limit	$12.42		'	'
Options exercise price range at end of period, Upper Limit	$47.80		'	'
Options exercisable at end of period	2,967,156		'	'
Options available for grant at end of period	'		'	4,460,337
Stock Options [Member]	'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'
Allocated Share-based Compensation Expense	530,000		'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'	'
Options available for grant at end of period	3,625,869	[1]	'	'
Restricted Stock [Member]	'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'
Allocated Share-based Compensation Expense	$115,000		'	'
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity	376,068		'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	188,034		'	'

[1]	*Shares available for grant as of MarchB 31, 2014 reduced by net restricted stock and restricted stock unit award and performance share and performance share unit award activity of 376,068 shares and 458,400

Shareholders_Equity_Transactio4

Shareholders' Equity Transactions Stock Options Outstanding by Exercise Price (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'10 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	0	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'2 years	'
Range of Exercise Price, Lower Limit	$12.42	'
Range of Exercise Price, Upper Limit	$47.80	'
Number Outstanding at end of period	4,419,069	'
Weighted Average Remaining Contractual Life	'4 years 9 months 13 days	'
Weighted Average Exercise Price	$23.97	$23.86
Number Exercisable At end of period	3,441,676	'
Weighted Average Exercise Price	$26.13	'
Range of Exercise Price 12.42 to 15.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$12.42	'
Range of Exercise Price, Upper Limit	$15	'
Number Outstanding at end of period	1,256,124	'
Weighted Average Remaining Contractual Life	'7 years 10 months 13 days	'
Weighted Average Exercise Price	$13.95	'
Number Exercisable At end of period	461,239	'
Weighted Average Exercise Price	$13.78	'
Range of Exercise Price 15.01 to 25.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$15.01	'
Range of Exercise Price, Upper Limit	$25	'
Number Outstanding at end of period	1,563,747	'
Weighted Average Remaining Contractual Life	'4 years 4 months 13 days	'
Weighted Average Exercise Price	$22.52	'
Number Exercisable At end of period	1,419,474	'
Weighted Average Exercise Price	$22.38	'
Range of Exercise Price 25.01 to 35.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$25.01	'
Range of Exercise Price, Upper Limit	$35	'
Number Outstanding at end of period	912,383	'
Weighted Average Remaining Contractual Life	'4 years 6 months 13 days	'
Weighted Average Exercise Price	$25.73	'
Number Exercisable At end of period	893,223	'
Weighted Average Exercise Price	$25.71	'
Range of Exercise Price 35.01 to 47.80 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$35.01	'
Range of Exercise Price, Upper Limit	$47.80	'
Number Outstanding at end of period	686,815	'
Weighted Average Remaining Contractual Life	'0 years 3 months 13 days	'
Weighted Average Exercise Price	$43.23	'
Number Exercisable At end of period	667,740	'
Weighted Average Exercise Price	$43.22	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	$125,156	$112,743
OCI before reclassifications	6,506	-132
Amount reclassified from accumulated OCI	184	266
Net current-period OCI	6,690	134
Ending Balance	131,846	112,877
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'
Net Sales	309,069	331,437
Cost of Products Sold	223,821	237,853
Service and interest costs	-708	-300
Interest Expense	-738	-1,010
Tax	-2,225	7,475
Accumulated Translation Adjustment [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	143,845	117,465
OCI before reclassifications	6,103	194
Amount reclassified from accumulated OCI	0	0
Net current-period OCI	6,103	194
Ending Balance	149,948	117,659
Accumulated Long-Term Notes Adjustment [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	-12,566	2,845
OCI before reclassifications	545	-1,692
Amount reclassified from accumulated OCI	0	0
Net current-period OCI	545	-1,692
Ending Balance	-12,021	1,153
Accumulated Defined Benefit Plans Adjustment [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	-5,414	-6,785
OCI before reclassifications	484	123
Amount reclassified from accumulated OCI	58	13
Net current-period OCI	542	136
Ending Balance	-4,872	-6,649
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'
Service and interest costs	58	15
Tax	0	-2
Total after tax	58	13
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	-709	-782
OCI before reclassifications	-626	1,243
Amount reclassified from accumulated OCI	126	253
Net current-period OCI	-500	1,496
Ending Balance	-1,209	714
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'
Total before tax	143	287
Tax	-17	-34
Total after tax	126	253
Foreign Exchange Contract [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'
Net Sales	10	-136
Commodity Contract [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'
Cost of Products Sold	133	356
Interest Rate Contract [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'
Interest Expense	$0	$67

Charges_Related_To_Restructuri2

Charges Related To Restructuring Activities (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	$4,485,000	$6,993,000	$4,979,000	$0
Restructuring Charges including Inventory Markdowns	2,240,000	9,336,000	11,395,000	10,534,000
Restructuring Reserve, Settled with Cash	-2,625,000	-11,844,000	-9,381,000	-5,555,000
Restructuring Reserve, Ending Balance	4,100,000	4,485,000	6,993,000	4,979,000
Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	3,986,000	5,211,000	4,905,000	0
Restructuring Charges including Inventory Markdowns	1,521,000	8,282,000	6,775,000	8,352,000
Restructuring Reserve, Settled with Cash	-1,752,000	-9,507,000	-6,469,000	-3,447,000
Restructuring Reserve, Ending Balance	3,755,000	3,986,000	5,211,000	4,905,000
Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	151,000	0	0
Restructuring Charges including Inventory Markdowns	0	0	491,000	277,000
Restructuring Reserve, Settled with Cash	0	-151,000	-340,000	-277,000
Restructuring Reserve, Ending Balance	0	0	151,000	0
Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	499,000	1,625,000	74,000	0
Restructuring Charges including Inventory Markdowns	0	698,000	1,725,000	1,788,000
Restructuring Reserve, Settled with Cash	-154,000	-1,824,000	-174,000	-1,714,000
Restructuring Reserve, Ending Balance	345,000	499,000	1,625,000	74,000
Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	6,000	0	0
Restructuring Charges including Inventory Markdowns	719,000	356,000	2,404,000	117,000
Restructuring Reserve, Settled with Cash	-719,000	-362,000	-2,398,000	-117,000
Restructuring Reserve, Ending Balance	0	0	6,000	0
NA/HME [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	2,805,000	3,747,000	3,092,000	'
Restructuring Charges including Inventory Markdowns	803,000	5,922,000	4,247,000	4,759,000
Restructuring Reserve, Settled with Cash	-1,120,000	-6,864,000	-3,592,000	-1,667,000
Restructuring Reserve, Ending Balance	2,488,000	2,805,000	3,747,000	3,092,000
NA/HME [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	2,805,000	3,747,000	3,092,000	'
Restructuring Charges including Inventory Markdowns	803,000	5,405,000	4,242,000	4,755,000
Restructuring Reserve, Settled with Cash	-1,120,000	-6,347,000	-3,587,000	-1,663,000
Restructuring Reserve, Ending Balance	2,488,000	2,805,000	3,747,000	3,092,000
NA/HME [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	0
Restructuring Reserve, Settled with Cash	0	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0
NA/HME [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	164,000	5,000	0
Restructuring Reserve, Settled with Cash	0	-164,000	-5,000	0
Restructuring Reserve, Ending Balance	0	0	0	0
NA/HME [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	353,000	0	4,000
Restructuring Reserve, Settled with Cash	0	-353,000	0	-4,000
Restructuring Reserve, Ending Balance	0	0	0	0
IPG [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	92,000	0	71,000	'
Restructuring Charges including Inventory Markdowns	1,059,000	267,000	35,000	123,000
Restructuring Reserve, Settled with Cash	-754,000	-175,000	-106,000	-52,000
Restructuring Reserve, Ending Balance	397,000	92,000	0	71,000
IPG [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	92,000	0	71,000	'
Restructuring Charges including Inventory Markdowns	340,000	267,000	35,000	123,000
Restructuring Reserve, Settled with Cash	-35,000	-175,000	-106,000	-52,000
Restructuring Reserve, Ending Balance	397,000	92,000	0	71,000
IPG [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	0
Restructuring Reserve, Settled with Cash	0	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0
IPG [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	0
Restructuring Reserve, Settled with Cash	0	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0
IPG [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	719,000	0	0	0
Restructuring Reserve, Settled with Cash	-719,000	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0
Europe [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	1,089,000	595,000	1,816,000	'
Restructuring Charges including Inventory Markdowns	378,000	1,640,000	2,093,000	5,466,000
Restructuring Reserve, Settled with Cash	-597,000	-1,146,000	-3,314,000	-3,650,000
Restructuring Reserve, Ending Balance	870,000	1,089,000	595,000	1,816,000
Europe [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	1,089,000	595,000	1,742,000	'
Restructuring Charges including Inventory Markdowns	378,000	1,640,000	817,000	3,288,000
Restructuring Reserve, Settled with Cash	-597,000	-1,146,000	-1,964,000	-1,546,000
Restructuring Reserve, Ending Balance	870,000	1,089,000	595,000	1,742,000
Europe [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	0	277,000
Restructuring Reserve, Settled with Cash	0	0	0	-277,000
Restructuring Reserve, Ending Balance	0	0	0	0
Europe [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	74,000	'
Restructuring Charges including Inventory Markdowns	0	0	53,000	1,788,000
Restructuring Reserve, Settled with Cash	0	0	-127,000	-1,714,000
Restructuring Reserve, Ending Balance	0	0	0	74,000
Europe [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	'
Restructuring Charges including Inventory Markdowns	0	0	1,223,000	113,000
Restructuring Reserve, Settled with Cash	0	0	-1,223,000	-113,000
Restructuring Reserve, Ending Balance	0	0	0	0
Asia/Pacific [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	499,000	2,651,000	0	'
Restructuring Charges including Inventory Markdowns	0	1,507,000	5,020,000	186,000
Restructuring Reserve, Settled with Cash	-154,000	-3,659,000	-2,369,000	-186,000
Restructuring Reserve, Ending Balance	345,000	499,000	2,651,000	0
Asia/Pacific [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	869,000	0	'
Restructuring Charges including Inventory Markdowns	0	970,000	1,681,000	186,000
Restructuring Reserve, Settled with Cash	0	-1,839,000	-812,000	-186,000
Restructuring Reserve, Ending Balance	0	0	869,000	0
Asia/Pacific [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	151,000	0	'
Restructuring Charges including Inventory Markdowns	0	0	491,000	0
Restructuring Reserve, Settled with Cash	0	-151,000	-340,000	0
Restructuring Reserve, Ending Balance	0	0	151,000	0
Asia/Pacific [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	499,000	1,625,000	0	'
Restructuring Charges including Inventory Markdowns	0	534,000	1,667,000	0
Restructuring Reserve, Settled with Cash	-154,000	-1,660,000	-42,000	0
Restructuring Reserve, Ending Balance	345,000	499,000	1,625,000	0
Asia/Pacific [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Reserve, Beginning Balance	0	6,000	0	'
Restructuring Charges including Inventory Markdowns	0	3,000	1,181,000	0
Restructuring Reserve, Settled with Cash	0	-9,000	-1,175,000	0
Restructuring Reserve, Ending Balance	$0	$0	$6,000	$0

Charges_Related_To_Restructuri3

Charges Related To Restructuring Activities Narrative (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	$2,240,000	$9,336,000	$11,395,000	$10,534,000
Restructuring Reserve, Settled with Cash	2,625,000	11,844,000	9,381,000	5,555,000
Restructuring and Related Activities, Expected Payout Period	'12 months	'	'	'
Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	1,521,000	8,282,000	6,775,000	8,352,000
Restructuring Reserve, Settled with Cash	1,752,000	9,507,000	6,469,000	3,447,000
Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	698,000	1,725,000	1,788,000
Restructuring Reserve, Settled with Cash	154,000	1,824,000	174,000	1,714,000
Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	491,000	277,000
Restructuring Reserve, Settled with Cash	0	151,000	340,000	277,000
Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	719,000	356,000	2,404,000	117,000
Restructuring Reserve, Settled with Cash	719,000	362,000	2,398,000	117,000
Europe [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	378,000	1,640,000	2,093,000	5,466,000
Restructuring Reserve, Settled with Cash	597,000	1,146,000	3,314,000	3,650,000
Europe [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	378,000	1,640,000	817,000	3,288,000
Restructuring Reserve, Settled with Cash	597,000	1,146,000	1,964,000	1,546,000
Europe [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	53,000	1,788,000
Restructuring Reserve, Settled with Cash	0	0	127,000	1,714,000
Europe [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	277,000
Restructuring Reserve, Settled with Cash	0	0	0	277,000
Europe [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	1,223,000	113,000
Restructuring Reserve, Settled with Cash	0	0	1,223,000	113,000
Asia Pacific [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	1,507,000	5,020,000	186,000
Restructuring Reserve, Settled with Cash	154,000	3,659,000	2,369,000	186,000
Asia Pacific [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	970,000	1,681,000	186,000
Restructuring Reserve, Settled with Cash	0	1,839,000	812,000	186,000
Asia Pacific [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	534,000	1,667,000	0
Restructuring Reserve, Settled with Cash	154,000	1,660,000	42,000	0
Asia Pacific [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	491,000	0
Restructuring Reserve, Settled with Cash	0	151,000	340,000	0
Asia Pacific [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	3,000	1,181,000	0
Restructuring Reserve, Settled with Cash	0	9,000	1,175,000	0
NA/HME [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	803,000	5,922,000	4,247,000	4,759,000
Restructuring Reserve, Settled with Cash	1,120,000	6,864,000	3,592,000	1,667,000
NA/HME [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	803,000	5,405,000	4,242,000	4,755,000
Restructuring Reserve, Settled with Cash	1,120,000	6,347,000	3,587,000	1,663,000
NA/HME [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	164,000	5,000	0
Restructuring Reserve, Settled with Cash	0	164,000	5,000	0
NA/HME [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	0
Restructuring Reserve, Settled with Cash	0	0	0	0
NA/HME [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	353,000	0	4,000
Restructuring Reserve, Settled with Cash	0	353,000	0	4,000
IPG [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	1,059,000	267,000	35,000	123,000
Restructuring Reserve, Settled with Cash	754,000	175,000	106,000	52,000
IPG [Member] \| Severance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	340,000	267,000	35,000	123,000
Restructuring Reserve, Settled with Cash	35,000	175,000	106,000	52,000
IPG [Member] \| Contract Termination [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	0
Restructuring Reserve, Settled with Cash	0	0	0	0
IPG [Member] \| Product Line Discontinuance [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	0	0	0	0
Restructuring Reserve, Settled with Cash	0	0	0	0
IPG [Member] \| Other [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring Charges including Inventory Markdowns	719,000	0	0	0
Restructuring Reserve, Settled with Cash	$719,000	$0	$0	$0

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details)	3 Months Ended
Income Taxes (Narrative) (Details)	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Effective Income Tax Rate, Continuing Operations	-14.10%	56.70%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	35.00%	35.00%

Net_Earnings_Loss_Per_Common_S2

Net Earnings (Loss) Per Common Share Computation of Basic and Diluted Net Earnings (Loss) Per Common Share (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Basic	'	'
Average common shares outstanding	32,013	31,902
Net Earnings (loss)	($17,976)	$35,181
Net earnings (loss) per common share	($0.56)	$1.10
Income (Loss) from Continuing Operations Attributable to Parent	-17,976	-5,708
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	0	40,889
Income (Loss) from Continuing Operations, Per Basic Share	($0.56)	($0.18)
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	$0	$1.28
Diluted	'	'
Average common shares outstanding	32,013	31,902
Shares related to convertible debt	0	0
Stock options and awards	288	32
Average common shares assuming dilution	32,301	31,934
Net Earnings (loss)	($17,976)	$35,181
Net Earnings (loss) per Share - Assuming Dilution	($0.56)	$1.10
Income (Loss) from Continuing Operations, Per Diluted Share	($0.56)	($0.18)
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share	$0	$1.28

Net_Earnings_Loss_Per_Common_S3

Net Earnings (Loss) Per Common Share Textuals (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	2,525,703	5,103,319
Antidilutive Share Granted, Average Exercise Price	$41.87	$41.87
Fair value stock price	$20.57	$15.41

Concentration_Of_Credit_Risk_D

Concentration Of Credit Risk (Details) (USD $)	Mar. 31, 2014
Concentration Risk [Line Items]	'
Retained Recourse Obligation For Events Of Default Under Contracts	$4,493,000
Events of Default Under Contract by Third Party	$40,528,000

Derivatives_Notional_Amounts_D

Derivatives Notional Amounts (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Foreign Exchange Forward [Member]

Minimum [Member]

Maximum [Member]

Not Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

EUR / AUD [Member]

EUR / DKK [Member]

AUD / EUR [Member]

AUD / GBP [Member]

EUR / AUD [Member]

EUR / DKK [Member]

DKK / SEK [Member]

EUR / CAD [Member]

EUR / CHF [Member]

EUR / GBP [Member]

EUR / SEK [Member]

AUD / CAD [Member]

EUR / NZD [Member]

GBP / CHF [Member]

GBP / SEK [Member]

NOK / CHF [Member]

AUD / NZD [Member]

EUR / NOK [Member]

Derivative [Line Items]

Derivative, Percentage of Forcasted Transactions With Currency Rate Exposure

60.00%

90.00%

Notional Amount

$44,300,000

$51,556,000

$2,100,000

$1,500,000

$5,548,000

$2,106,000

$2,966,000

$5,612,000

$24,120,000

$1,482,000

$15,138,000

$5,000,000

$678,000

$6,636,000

$22,970,000

$116,359,000

$135,009,000

$500,000

$1,096,000

$1,382,000

$3,981,000

$5,337,000

$1,650,000

$10,600,000

$11,730,000

$339,000

$486,000

$39,317,000

$51,106,000

$2,132,000

$2,686,000

$1,204,000

$1,734,000

$2,485,000

$8,683,000

$5,960,000

$1,326,000

$1,710,000

$2,322,000

$2,654,000

$23,440,000

$29,614,000

$2,790,000

$3,432,000

$1,323,000

$5,679,000

$6,959,000

$661,000

$837,000

$1,644,000

$2,078,000

$2,575,000

$3,418,000

$883,000

$2,480,000

$3,135,000

Unrealized Gain (Loss)

-1,373,000

-781,000

-16,000

-3,000

-5,000

-29,000

-94,000

-54,000

-207,000

-66,000

-8,000

4,000

-767,000

-168,000

-85,000

-45,000

-47,000

-5,000

58,000

174,000

102,000

71,000

-1,000

32,000

1,000

-601,000

-501,000

11,000

75,000

-18,000

224,000

-111,000

-16,000

-26,000

-78,000

-101,000

24,000

31,000

-6,000

31,000

66,000

Amount of Gain (Loss) Recognized in Income on Derivatives

($345,000)

($1,171,000)

($345,000)

($1,171,000)

($52,000)

($35,000)

($9,000)

($6,000)

$6,000

($184,000)

($544,000)

($40,000)

$18,000

($86,000)

$1,000

$13,000

($598,000)

Derivatives_Balance_Sheet_Loca

Derivatives Balance Sheet Location (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
			Foreign Exchange Forward [Member]	Foreign Exchange Forward [Member]	Foreign Exchange Forward [Member]	Foreign Exchange Forward [Member]	Foreign Exchange Forward [Member]	Foreign Exchange Forward [Member]	Interest Rate Swap [Member]	Interest Rate Swap [Member]
					Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]	Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]	'	'	'	'	'	'	'	'	'	'
Notional Amount of Derivatives, Matured During Period	'	'	$33,623,000	$33,494,000	'	'	'	'	'	'
Derivative Assets	599,000	789,000	'	'	568,000	414,000	31,000	375,000	0	0
Interest Rate Derivative Liabilities, at Fair Value	$2,321,000	$1,212,000	'	'	$1,941,000	$1,195,000	$376,000	$5,000	$4,000	$12,000

Derivatives_Gain_Loss_in_State

Derivatives Gain (Loss) in Statement of Finacial Position (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flow Hedging [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	($374,000)	$1,864,000
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-126,000	-287,000
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	0	57,000
Amount of Gain (Loss) Recognized in Income on Derivatives	-143,000	-220,000
Sales [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Income	-10,000	136,000
Cost of Sales [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Income	'	-356,000
Derivative Instruments, Gain (Loss) Recognized in Income	-133,000	'
Foreign Exchange Forward [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain (Loss) Recognized in Income on Derivatives	-345,000	-1,171,000
Foreign Exchange Forward [Member] \| Cash Flow Hedging [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	-382,000	1,601,000
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-126,000	-220,000
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	0	57,000
Foreign Exchange Forward [Member] \| Selling General and Administrative Expense [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Income	-345,000	'
Derivative Instruments, Gain (Loss) Recognized in Income	'	-1,171,000
Interest Rate Swap [Member] \| Cash Flow Hedging [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	8,000	263,000
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	0	-67,000
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	0	0
Interest Rate Swap [Member] \| Interest Expense [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Income	-11,000	-226,000
Not Designated as Hedging Instrument [Member] \| Foreign Exchange Forward [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain (Loss) Recognized in Income on Derivatives	-345,000	-1,171,000
EUR / AUD [Member] \| Not Designated as Hedging Instrument [Member] \| Foreign Exchange Forward [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Amount of Gain (Loss) Recognized in Income on Derivatives	$0	($35,000)

Fair_Values_of_Financial_Instr1

Fair Values of Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Interest Rate Derivative Liabilities, at Fair Value	$2,321	$1,212
Fair Value, Measurements, Recurring [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	-1,718	-411
Interest Rate Derivative Liabilities, at Fair Value	-4	-12
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Liabilities, at Fair Value	0	0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	-1,718	-411
Interest Rate Derivative Liabilities, at Fair Value	-4	-12
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Liabilities, at Fair Value	$0	$0

Fair_Values_of_Financial_Instr2

Fair Values of Financial Instruments Details of Book Value and Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	$21,260	$29,785	$25,081	$38,791
Installment receivables, net	1,590	1,562	'	'
Other current assets	39,036	41,172	'	'
Cash and Cash Equivalents [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	21,260	29,785	'	'
Cash and Cash Equivalents [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents	21,260	29,785	'	'
Other Assets [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other Investments	990	998	'	'
Other Assets [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other Investments	990	998	'	'
Accounts and Notes Receivable, Net [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Installment receivables, net	3,100	2,819	'	'
Accounts and Notes Receivable, Net [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Installment receivables, net	3,100	2,819	'	'
Debt [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Long-term debt (including current maturities of long-term debt)	-48,957	-45,286	'	'
Debt [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Long-term debt (including current maturities of long-term debt)	-48,471	-46,124	'	'
Foreign Exchange Forward [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other current assets	599	789	'	'
Accrued Expenses	-2,317	-1,200	'	'
Foreign Exchange Forward [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other current assets	599	789	'	'
Accrued Expenses	-2,317	-1,200	'	'
Interest Rate Swap [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Accrued Expenses	-4	-12	'	'
Interest Rate Swap [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Accrued Expenses	($4)	($12)	'	'

Business_Segments_Information_

Business Segments (Information by Segment) (Details) (USD $)	3 Months Ended				12 Months Ended
	Mar. 31, 2014		Mar. 31, 2013		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	$2,240,000		'		$9,336,000	$11,395,000	$10,534,000	'
Revenue from external customers	309,069,000		331,437,000		'	'	'	'
Related Party Transaction, Other Revenues from Transactions with Related Party	28,120,000		28,778,000		'	'	'	'
Restructuring Charges	2,240,000		2,522,000		'	'	'	'
Earnings (loss) before income taxes	-15,751,000		-13,183,000		'	'	'	'
Restructuring Reserve, Settled with Cash	-2,625,000		'		-11,844,000	-9,381,000	-5,555,000	'
Restructuring Reserve	4,100,000		'		4,485,000	6,993,000	4,979,000	0
North America/HME [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Revenue from external customers	129,110,000		151,882,000		'	'	'	'
Related Party Transaction, Other Revenues from Transactions with Related Party	18,673,000		18,836,000		'	'	'	'
Restructuring Charges	803,000		1,679,000		'	'	'	'
Earnings (loss) before income taxes	-16,799,000		-11,179,000		'	'	'	'
Institutional Products Group [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Revenue from external customers	25,136,000		29,224,000		'	'	'	'
Related Party Transaction, Other Revenues from Transactions with Related Party	1,573,000		1,107,000		'	'	'	'
Restructuring Charges	1,059,000		188,000		'	'	'	'
Earnings (loss) before income taxes	-251,000		474,000		'	'	'	'
Europe [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	378,000		'		1,640,000	2,093,000	5,466,000	'
Revenue from external customers	142,768,000		137,634,000		'	'	'	'
Related Party Transaction, Other Revenues from Transactions with Related Party	1,682,000		1,953,000		'	'	'	'
Restructuring Charges	378,000		115,000		'	'	'	'
Earnings (loss) before income taxes	9,246,000		5,843,000		'	'	'	'
Restructuring Reserve, Settled with Cash	-597,000		'		-1,146,000	-3,314,000	-3,650,000	'
Restructuring Reserve	870,000		'		1,089,000	595,000	1,816,000	'
Asia Pacific [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		1,507,000	5,020,000	186,000	'
Revenue from external customers	12,055,000		12,697,000		'	'	'	'
Related Party Transaction, Other Revenues from Transactions with Related Party	6,192,000		6,882,000		'	'	'	'
Restructuring Charges	0		540,000		'	'	'	'
Earnings (loss) before income taxes	-2,801,000		-2,261,000		'	'	'	'
Restructuring Reserve, Settled with Cash	-154,000		'		-3,659,000	-2,369,000	-186,000	'
Restructuring Reserve	345,000		'		499,000	2,651,000	0	'
All Other Segments [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Earnings (loss) before income taxes	-5,146,000	[1]	-6,060,000	[1]	'	'	'	'
NA/HME [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	803,000		'		5,922,000	4,247,000	4,759,000	'
Restructuring Reserve, Settled with Cash	-1,120,000		'		-6,864,000	-3,592,000	-1,667,000	'
Restructuring Reserve	2,488,000		'		2,805,000	3,747,000	3,092,000	'
IPG [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	1,059,000		'		267,000	35,000	123,000	'
Restructuring Reserve, Settled with Cash	-754,000		'		-175,000	-106,000	-52,000	'
Restructuring Reserve	397,000		'		92,000	0	71,000	'
Severance [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	1,521,000		'		8,282,000	6,775,000	8,352,000	'
Restructuring Reserve, Settled with Cash	-1,752,000		'		-9,507,000	-6,469,000	-3,447,000	'
Restructuring Reserve	3,755,000		'		3,986,000	5,211,000	4,905,000	0
Severance [Member] \| Europe [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	378,000		'		1,640,000	817,000	3,288,000	'
Restructuring Reserve, Settled with Cash	-597,000		'		-1,146,000	-1,964,000	-1,546,000	'
Restructuring Reserve	870,000		'		1,089,000	595,000	1,742,000	'
Severance [Member] \| Asia Pacific [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		970,000	1,681,000	186,000	'
Restructuring Reserve, Settled with Cash	0		'		-1,839,000	-812,000	-186,000	'
Restructuring Reserve	0		'		0	869,000	0	'
Severance [Member] \| NA/HME [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	803,000		'		5,405,000	4,242,000	4,755,000	'
Restructuring Reserve, Settled with Cash	-1,120,000		'		-6,347,000	-3,587,000	-1,663,000	'
Restructuring Reserve	2,488,000		'		2,805,000	3,747,000	3,092,000	'
Severance [Member] \| IPG [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	340,000		'		267,000	35,000	123,000	'
Restructuring Reserve, Settled with Cash	-35,000		'		-175,000	-106,000	-52,000	'
Restructuring Reserve	397,000		'		92,000	0	71,000	'
Product Line Discontinuance [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	491,000	277,000	'
Restructuring Reserve, Settled with Cash	0		'		-151,000	-340,000	-277,000	'
Restructuring Reserve	0		'		0	151,000	0	0
Product Line Discontinuance [Member] \| Europe [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	0	277,000	'
Restructuring Reserve, Settled with Cash	0		'		0	0	-277,000	'
Restructuring Reserve	0		'		0	0	0	'
Product Line Discontinuance [Member] \| Asia Pacific [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	491,000	0	'
Restructuring Reserve, Settled with Cash	0		'		-151,000	-340,000	0	'
Restructuring Reserve	0		'		0	151,000	0	'
Product Line Discontinuance [Member] \| NA/HME [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	0	0	'
Restructuring Reserve, Settled with Cash	0		'		0	0	0	'
Restructuring Reserve	0		'		0	0	0	'
Product Line Discontinuance [Member] \| IPG [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	0	0	'
Restructuring Reserve, Settled with Cash	0		'		0	0	0	'
Restructuring Reserve	0		'		0	0	0	'
Contract Termination [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		698,000	1,725,000	1,788,000	'
Restructuring Reserve, Settled with Cash	-154,000		'		-1,824,000	-174,000	-1,714,000	'
Restructuring Reserve	345,000		'		499,000	1,625,000	74,000	0
Contract Termination [Member] \| Europe [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	53,000	1,788,000	'
Restructuring Reserve, Settled with Cash	0		'		0	-127,000	-1,714,000	'
Restructuring Reserve	0		'		0	0	74,000	'
Contract Termination [Member] \| Asia Pacific [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		534,000	1,667,000	0	'
Restructuring Reserve, Settled with Cash	-154,000		'		-1,660,000	-42,000	0	'
Restructuring Reserve	345,000		'		499,000	1,625,000	0	'
Contract Termination [Member] \| NA/HME [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		164,000	5,000	0	'
Restructuring Reserve, Settled with Cash	0		'		-164,000	-5,000	0	'
Restructuring Reserve	0		'		0	0	0	'
Contract Termination [Member] \| IPG [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	0	0	'
Restructuring Reserve, Settled with Cash	0		'		0	0	0	'
Restructuring Reserve	0		'		0	0	0	'
Other [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	719,000		'		356,000	2,404,000	117,000	'
Restructuring Reserve, Settled with Cash	-719,000		'		-362,000	-2,398,000	-117,000	'
Restructuring Reserve	0		'		0	6,000	0	0
Other [Member] \| Europe [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		0	1,223,000	113,000	'
Restructuring Reserve, Settled with Cash	0		'		0	-1,223,000	-113,000	'
Restructuring Reserve	0		'		0	0	0	'
Other [Member] \| Asia Pacific [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		3,000	1,181,000	0	'
Restructuring Reserve, Settled with Cash	0		'		-9,000	-1,175,000	0	'
Restructuring Reserve	0		'		0	6,000	0	'
Other [Member] \| NA/HME [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	0		'		353,000	0	4,000	'
Restructuring Reserve, Settled with Cash	0		'		-353,000	0	-4,000	'
Restructuring Reserve	0		'		0	0	0	'
Other [Member] \| IPG [Member]	'		'		'	'	'	'
Segment Reporting Information [Line Items]	'		'		'	'	'	'
Restructuring Charges including Inventory Markdowns	719,000		'		0	0	0	'
Restructuring Reserve, Settled with Cash	-719,000		'		0	0	0	'
Restructuring Reserve	$0		'		$0	$0	$0	'

[1]	The information by segment is as follows (in thousands): For the Three Months EndedB MarchB 31, 2014B MarchB 31, 2013Revenues from external customers North America/HME$129,110B $151,882Institutional Products Group25,136B 29,224Europe142,768B 137,634Asia/Pacific12,055B 12,697Consolidated$309,069B $331,437Intersegment revenues North America/HME$18,673B $18,836Institutional Products Group1,573B 1,107Europe1,682B 1,953Asia/Pacific6,192B 6,882Consolidated$28,120B $28,778Restructuring charges before income taxes North America/HME$803B $1,679Institutional Products Group1,059B 188Europe378B 115Asia/PacificbB 540Consolidated$2,240B $2,522Earnings (loss) before income taxes North America/HME$(16,799)B $(11,179)Institutional Products Group(251)B 474Europe9,246B 5,843Asia/Pacific(2,801)B (2,261)All Other (1)(5,146)B (6,060)Consolidated$(15,751)B $(13,183) ________________________(1)Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments.

Contingencies_Contingencies_De

Contingencies Contingencies (Details) (USD $)	0 Months Ended
Contingencies Contingencies (Details) (USD $)	Dec. 21, 2012	Mar. 31, 2014
Loss Contingencies [Line Items]	'	'
Consent Decree Court Approval Date	21-Dec-12	'
Agreement to Sell Operations Date	31-Dec-13	'
Loss Contingency Accrual, at Carrying Value	'	$2,237,000
Loss Contingency Accrual Carrying Value, Net of Tax	'	2,100,000
NA/HME [Member]	'	'
Loss Contingencies [Line Items]	'	'
Loss Contingency Accrual, at Carrying Value	'	1,171,000
Asia Pacific [Member]	'	'
Loss Contingencies [Line Items]	'	'
Loss Contingency Accrual, at Carrying Value	'	$929,000

Supplemental_Guarantor_Informa2

Supplemental Guarantor Information Consolidating Condensed Statements of Operations (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Feb. 17, 2007
			The Company (Parent) [Member]	The Company (Parent) [Member]	Combined Guarantor Subsidiaries [Member]	Combined Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Eliminations [Member]	Eliminations [Member]	Convertible Senior Subordinated Debentures February 2027 [Member]	Convertible Senior Subordinated Debentures February 2027 [Member]
											Convertible Subordinated Debt [Member]	Convertible Subordinated Debt [Member]
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'
Net sales	$309,069,000	$331,437,000	$50,109,000	$60,909,000	$106,454,000	$118,436,000	$173,800,000	$173,925,000	($21,294,000)	($21,833,000)	'	'
Interest Rate	'	'	'	'	'	'	'	'	'	'	4.13%	'
Debt Instrument, Face Amount	'	'	'	'	'	'	'	'	'	'	'	135,000,000
Cost of Goods Sold	223,821,000	237,853,000	45,704,000	52,353,000	77,584,000	85,849,000	121,890,000	121,705,000	-21,357,000	-22,054,000	'	'
Gross Profit	85,248,000	93,584,000	4,405,000	8,556,000	28,870,000	32,587,000	51,910,000	52,220,000	63,000	221,000	'	'
Selling, general and administrative expense	98,021,000	103,235,000	31,650,000	34,863,000	22,268,000	23,051,000	44,103,000	43,977,000	0	1,344,000	'	'
Restructuring Charges	2,240,000	2,522,000	1,164,000	1,671,000	-95,000	0	1,171,000	851,000	0	0	'	'
Asset write-downs related to restructuring activities	638,000	0	'	'	'	'	'	'	'	'	'	'
Income (Loss) from Equity Method Investments	0	0	10,310,000	48,018,000	6,931,000	5,808,000	-36,000	65,000	-17,205,000	-53,891,000	'	'
Interest Income (Expense), Net	738,000	1,010,000	-284,000	-45,000	865,000	436,000	157,000	619,000	0	0	'	'
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	-15,751,000	-13,183,000	-17,815,000	20,085,000	12,763,000	14,908,000	6,443,000	6,838,000	-17,142,000	-55,014,000	'	'
Income Tax Expense (Benefit)	2,225,000	-7,475,000	161,000	-15,096,000	0	-25,000	2,064,000	7,646,000	0	0	'	'
Income (Loss) from Continuing Operations Attributable to Parent	-17,976,000	-5,708,000	'	35,181,000	'	14,933,000	'	-808,000	'	-55,014,000	'	'
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	0	40,889,000	'	0	'	40,889,000	'	0	'	0	'	'
Net Earnings (loss)	-17,976,000	35,181,000	-17,976,000	35,181,000	12,763,000	55,822,000	4,379,000	-808,000	-17,142,000	-55,014,000	'	'
Other Comprehensive Income (Loss), Net of Tax	6,690,000	134,000	6,690,000	134,000	-2,290,000	-2,186,000	8,955,000	1,787,000	-6,665,000	399,000	'	'
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	($11,286,000)	$35,315,000	($11,286,000)	$35,315,000	$10,473,000	$53,636,000	$13,334,000	$979,000	($23,807,000)	($54,615,000)	'	'

Supplemental_Guarantor_Informa3

Supplemental Guarantor Information Consolidating Condensed Balance Sheets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Current Assets	'	'	'	'
Cash and cash equivalents	$21,260	$29,785	$25,081	$38,791
Trade receivables, net	186,919	188,622	'	'
Installment receivables, net	1,590	1,562	'	'
Inventories, net	165,343	155,637	'	'
Deferred income taxes	2,714	2,761	'	'
Due from Affiliate, Current	0	0	'	'
Other current assets	39,036	41,172	'	'
Total Current Assets	416,862	419,539	'	'
Investment in subsidiaries	0	0	'	'
Intercompany advances, net	0	0	'	'
Other Assets	46,030	45,936	'	'
Other Intangibles	61,064	62,584	'	'
Property and Equipment, net	103,745	106,149	'	'
Goodwill	468,314	462,226	'	'
Total Assets	1,096,015	1,096,434	'	'
Current Liabilities	'	'	'	'
Accounts payable	124,442	116,704	'	'
Accrued expenses	131,345	133,100	'	'
Accrued income taxes	12,271	12,259	'	'
Due to Affiliate, Current	0	0	'	'
Short-term debt and current maturities of long-term obligations	1,763	14,102	'	'
Total Current Liabilities	269,821	276,165	'	'
Long-Term Debt	47,194	31,184	'	'
Other Long-Term Obligations	119,089	118,276	'	'
Inercompany advances, net	0	0	'	'
Total Shareholders' Equity	659,911	670,809	'	'
Total Liabilities and Shareholders' Equity	1,096,015	1,096,434	'	'
The Company (Parent) [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	2,733	1,401	1,984	5,774
Trade receivables, net	62,104	72,272	'	'
Installment receivables, net	0	0	'	'
Inventories, net	21,169	30,806	'	'
Deferred income taxes	0	0	'	'
Due from Affiliate, Current	8,750	4,179	'	'
Other current assets	8,643	9,970	'	'
Total Current Assets	103,399	118,628	'	'
Investment in subsidiaries	1,492,163	1,475,156	'	'
Intercompany advances, net	974,444	959,071	'	'
Other Assets	42,655	42,831	'	'
Other Intangibles	543	466	'	'
Property and Equipment, net	33,904	35,169	'	'
Goodwill	0	0	'	'
Total Assets	2,647,108	2,631,321	'	'
Current Liabilities	'	'	'	'
Accounts payable	51,340	42,521	'	'
Accrued expenses	29,871	30,314	'	'
Accrued income taxes	4,220	5,375	'	'
Due to Affiliate, Current	45,945	42,314	'	'
Short-term debt and current maturities of long-term obligations	794	13,118	'	'
Total Current Liabilities	132,170	133,642	'	'
Long-Term Debt	41,811	25,642	'	'
Other Long-Term Obligations	53,359	53,470	'	'
Inercompany advances, net	1,759,857	1,747,758	'	'
Total Shareholders' Equity	659,911	670,809	'	'
Total Liabilities and Shareholders' Equity	2,647,108	2,631,321	'	'
Combined Guarantor Subsidiaries [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	212	313	199	1,018
Trade receivables, net	29,569	28,317	'	'
Installment receivables, net	557	452	'	'
Inventories, net	27,076	27,472	'	'
Deferred income taxes	0	0	'	'
Due from Affiliate, Current	521	380	'	'
Other current assets	507	568	'	'
Total Current Assets	58,442	57,502	'	'
Investment in subsidiaries	458,521	450,021	'	'
Intercompany advances, net	1,639,111	1,620,683	'	'
Other Assets	1,320	1,061	'	'
Other Intangibles	16,272	17,109	'	'
Property and Equipment, net	16,914	17,774	'	'
Goodwill	16,660	16,660	'	'
Total Assets	2,207,240	2,180,810	'	'
Current Liabilities	'	'	'	'
Accounts payable	7,834	7,237	'	'
Accrued expenses	16,351	17,228	'	'
Accrued income taxes	0	0	'	'
Due to Affiliate, Current	1,956	2,124	'	'
Short-term debt and current maturities of long-term obligations	8	8	'	'
Total Current Liabilities	26,149	26,597	'	'
Long-Term Debt	41	61	'	'
Other Long-Term Obligations	0	0	'	'
Inercompany advances, net	974,811	959,172	'	'
Total Shareholders' Equity	1,206,239	1,194,980	'	'
Total Liabilities and Shareholders' Equity	2,207,240	2,180,810	'	'
Combined Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	18,315	28,071	22,898	31,999
Trade receivables, net	95,246	88,033	'	'
Installment receivables, net	1,033	1,110	'	'
Inventories, net	119,646	100,444	'	'
Deferred income taxes	2,714	2,761	'	'
Due from Affiliate, Current	49,043	44,292	'	'
Other current assets	32,903	35,461	'	'
Total Current Assets	318,900	300,172	'	'
Investment in subsidiaries	0	0	'	'
Intercompany advances, net	181,460	179,451	'	'
Other Assets	2,055	2,044	'	'
Other Intangibles	44,249	45,009	'	'
Property and Equipment, net	52,927	53,206	'	'
Goodwill	451,654	445,566	'	'
Total Assets	1,051,245	1,025,448	'	'
Current Liabilities	'	'	'	'
Accounts payable	65,268	66,946	'	'
Accrued expenses	88,140	90,385	'	'
Accrued income taxes	8,051	6,884	'	'
Due to Affiliate, Current	10,412	4,413	'	'
Short-term debt and current maturities of long-term obligations	961	976	'	'
Total Current Liabilities	172,832	169,604	'	'
Long-Term Debt	5,342	5,481	'	'
Other Long-Term Obligations	65,730	64,806	'	'
Inercompany advances, net	60,347	52,275	'	'
Total Shareholders' Equity	746,994	733,282	'	'
Total Liabilities and Shareholders' Equity	1,051,245	1,025,448	'	'
Eliminations [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Trade receivables, net	0	0	'	'
Installment receivables, net	0	0	'	'
Inventories, net	-2,548	-3,085	'	'
Deferred income taxes	0	0	'	'
Due from Affiliate, Current	-58,314	-48,851	'	'
Other current assets	-3,017	-4,827	'	'
Total Current Assets	-63,879	-56,763	'	'
Investment in subsidiaries	-1,950,684	-1,925,177	'	'
Intercompany advances, net	-2,795,015	-2,759,205	'	'
Other Assets	0	0	'	'
Other Intangibles	0	0	'	'
Property and Equipment, net	0	0	'	'
Goodwill	0	0	'	'
Total Assets	-4,809,578	-4,741,145	'	'
Current Liabilities	'	'	'	'
Accounts payable	0	0	'	'
Accrued expenses	-3,017	-4,827	'	'
Accrued income taxes	0	0	'	'
Due to Affiliate, Current	-58,313	-48,851	'	'
Short-term debt and current maturities of long-term obligations	0	0	'	'
Total Current Liabilities	-61,330	-53,678	'	'
Long-Term Debt	0	0	'	'
Other Long-Term Obligations	0	0	'	'
Inercompany advances, net	-2,795,015	-2,759,205	'	'
Total Shareholders' Equity	-1,953,233	-1,928,262	'	'
Total Liabilities and Shareholders' Equity	($4,809,578)	($4,741,145)	'	'

Supplemental_Guarantor_Informa4

Supplemental Guarantor Information Consolidating Condensed Statement of Cash Flows (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	($7,020)	($35,303)
Investing Activities	'	'
Purchases of property and equipment	-3,626	-3,865
Proceeds from sale of property and equipment	1	4
Proceeds from Divestiture of Business, net	0	144,681
Other long-term assets	-197	-108
Other	-144	-19
Net Cash Used for Investing Activities	-3,966	140,693
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	62,525	115,950
Payments on revolving lines of credit and long-term borrowings	-60,195	-234,696
Proceeds from Stock Options Exercised	85	0
Payment of dividends	-396	-396
Net Cash Provided (Used) by Financing Activities	2,019	-119,142
Effect of exchange rate changes on cash	442	42
Increase (decrease) in cash and cash equivalents	-8,525	-13,710
Cash and cash equivalents at beginning of year	29,785	38,791
Cash and cash equivalents at end of year	21,260	25,081
The Company (Parent) [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	-1,033	9,297
Investing Activities	'	'
Purchases of property and equipment	-649	-2,223
Proceeds from sale of property and equipment	0	0
Proceeds from Divestiture of Business, net	'	0
Other long-term assets	-193	-108
Other	-144	107,368
Net Cash Used for Investing Activities	-986	105,037
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	61,547	114,762
Payments on revolving lines of credit and long-term borrowings	-57,885	-232,490
Proceeds from Stock Options Exercised	85	'
Payment of dividends	-396	-396
Net Cash Provided (Used) by Financing Activities	3,351	-118,124
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	1,332	-3,790
Cash and cash equivalents at beginning of year	1,401	5,774
Cash and cash equivalents at end of year	2,733	1,984
Combined Guarantor Subsidiaries [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	2,824	-89,758
Investing Activities	'	'
Purchases of property and equipment	-615	-580
Proceeds from sale of property and equipment	0	0
Proceeds from Divestiture of Business, net	'	144,681
Other long-term assets	0	0
Other	0	-52,956
Net Cash Used for Investing Activities	-615	91,145
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	0	0
Payments on revolving lines of credit and long-term borrowings	-2,310	-2,206
Proceeds from Stock Options Exercised	0	'
Payment of dividends	0	0
Net Cash Provided (Used) by Financing Activities	-2,310	-2,206
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	-101	-819
Cash and cash equivalents at beginning of year	313	1,018
Cash and cash equivalents at end of year	212	199
Combined Non-Guarantor Subsidiaries [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	-8,811	-7,929
Investing Activities	'	'
Purchases of property and equipment	-2,362	-1,062
Proceeds from sale of property and equipment	1	4
Proceeds from Divestiture of Business, net	'	0
Other long-term assets	-4	0
Other	0	0
Net Cash Used for Investing Activities	-2,365	-1,058
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	978	1,188
Payments on revolving lines of credit and long-term borrowings	0	0
Proceeds from Stock Options Exercised	0	'
Payment of dividends	0	-1,344
Net Cash Provided (Used) by Financing Activities	978	-156
Effect of exchange rate changes on cash	442	42
Increase (decrease) in cash and cash equivalents	-9,756	-9,101
Cash and cash equivalents at beginning of year	28,071	31,999
Cash and cash equivalents at end of year	18,315	22,898
Eliminations [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	0	53,087
Investing Activities	'	'
Purchases of property and equipment	0	0
Proceeds from sale of property and equipment	0	0
Proceeds from Divestiture of Business, net	'	0
Other long-term assets	0	0
Other	0	-54,431
Net Cash Used for Investing Activities	0	-54,431
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	0	0
Payments on revolving lines of credit and long-term borrowings	0	0
Proceeds from Stock Options Exercised	0	'
Payment of dividends	0	1,344
Net Cash Provided (Used) by Financing Activities	0	1,344
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of year	0	0
Cash and cash equivalents at end of year	$0	$0